Enhanced Production of Core Lipids in Oleaginous Yeasts

RELATED APPLICATION

This application claims the benefit of priority to U.S. Provisional Patent Application serial number 62/097,781, filed December 30, 2014.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 11, 2015, is named NGX03825SL.txt and is 575,737 bytes in size.

BACKGROUND

Lipids are indispensable ingredients in the food and cosmetics industries, and they are important precursors in the biodiesel and biochemical industries. Many oleaginous microorganisms produce lipids, including the well-characterized yeast Yarrowia lipolytica.

Oleaginous microorganisms can be easily and cost-effectively grown on large scale, which suggests broad applicability for biodiesel and biochemical production.

Microorganisms may also be engineered to produce high-value products for the food and beverage industries. Further, these products are typically sequestered within the microorganisms, which can facilitate their isolation and purification.

Microorganisms produce lipid products at different rates and with different efficiencies. Lipid production in eukaryotic organisms generally proceeds by the oxidation of pyruvate to acetyl-CoA in the mitochondria via pyruvate dehydrogenase and the subsequent export of acetyl-CoA to the cytosol via the metabolic intermediate citrate. Mitochondrial pyruvate oxidation and citrate export results in a net accumulation of reduced nicotinamide adenine dinucleotide (NADH) in the mitochondria. The

accumulation of NADH in the mitochondria is suboptimal for lipid production, however, in part because mitochondrial NADH cannot reduce cytosolic ketones, which results in a lower overall lipid yield.

The lipid yield of oleaginous organisms can be increased by the up-regulation, down-regulation, or deletion of genes implicated in a lipid pathway. The successful modulation of enzymes, however, is unpredictable at best. For example, overexpressing the type 2 diacylglycerol acyltransferase from Mortierella alpine in Y. lipolytica has no significant effect on lipid content (U.S. Patent No. 7,198,937; hereby incorporated by reference).

SUMMARY

In some aspects, the invention relates to a transformed cell, comprising a first genetic modification, and a second genetic modification, wherein said first genetic modification increases the activity of a phosphoketolase protein in the cell, and said second genetic modification increases the activity of a phosphate acetyltransferase protein in the cell.

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, a second genetic modification, a third genetic modification, and a fourth genetic modification, wherein said first genetic modification increases the activity of a phosphoketolase protein in the cell, said second genetic modification increases the activity of a phosphate acetyltransferase protein in the cell, said third genetic modification increases the activity of a fructose- 1,6-bisphosphatase protein in the cell, and said fourth genetic modification decreases the activity of a phosphofructokinase protein in the cell.

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, a second genetic modification, and a third genetic modification, wherein said first genetic modification increases the activity of a pyruvate decarboxylase protein in the cell, said second genetic modification increases the activity of a phosphate acetyltransferase protein in the cell, and said third genetic modification increases the activity of an acetate kinase in the cell.

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, a second genetic modification, and a third genetic modification, wherein said first genetic modification increases the activity of a citrate/oxaloacetate mitochondrial transporter protein in the cell, said second genetic modification increases the activity of a cytosolic malic enzyme protein in the cell, and said third genetic modification increases the activity of a cytosolic pyruvate carboxylase protein in the cell.

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, and a second genetic modification, wherein said first genetic modification increases the activity of a citrate/oxaloacetate mitochondrial transporter protein in the cell, and said second genetic modification increases the NADH-specific enoyl acyl-carrier reductase activity of the cell. In some aspects, the invention relates to a product derived from a transformed cell of the invention. In some embodiments, the product comprises an oil, lipid, fatty acid, fatty alcohol, triacylglyceride, isoprenoid, or farnesene. The product may comprise stearic acid, oleic acid, linoleic acid, capric acid, caprylic acid, caproic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, or squalene. For example, the product may be oleic acid.

In some aspects, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a phosphoketolase protein, and transforming said cell with a second nucleotide sequence that encodes a phosphate acetyltransferase protein.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a phosphoketolase protein, transforming said cell with a second nucleotide sequence that encodes a phosphate acetyltransferase protein, transforming said cell with a third nucleotide sequence that encodes a fructose-l,6-bisphosphatase protein, and transforming said cell with a fourth nucleotide sequence that decreases that decreases the activity of a native phosphofructokinase protein in the cell.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a pyruvate decarboxylase protein, transforming said cell with a second nucleotide sequence that encodes a phosphate acetyltransferase protein, and transforming said cell with a third nucleotide sequence that encodes an acetate kinase protein.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein, transforming said cell with a second nucleotide sequence that encodes a cytosolic malic enzyme protein, and transforming said cell with a third nucleotide sequence that encodes a cytosolic pyruvate carboxylase protein.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein, and transforming said cell with a second nucleotide sequence. The second nucleotide sequence may either encode a NADH specific enoyl acyl-carrier reductase protein, or the second nucleotide sequence may be capable of recombining with a nucleotide sequence in a native type I fatty acid synthase enoyl reductase gene; and transformation of the cell with the second nucleotide sequence may increase the NADH specific enoyl acyl-carrier reductase activity of the cell.

The transformed cell may be selected from the group consisting of algae, bacteria, molds, fungi, plants, and yeasts. The cell may be a yeast. For example, the cell may be a yeast selected from the group consisting of Arxula adeninivorans, Saccharomyces cerevisiae, and Yarrowia lipolytica.

These and other features, aspects, and advantages of the present invention will become better understood with reference to the following description, drawings, and claims. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 depicts pathways for generation of acetyl-CoA and NADPH in unmodified yeast.

Figure 2 depicts a novel phosphoketolase pathway.

Figure 3 depicts a novel phosphoketolase pathway.

Figure 4 depicts a novel pyruvate decarboxylase pathway.

Figure 5 depicts a novel citrate exporter pathway.

Figure 6 depicts a novel citrate exporter pathway.

Figure 7 is a map of the pNC582 construct, used to overexpress the phosphate acetyl transferase gene from Bacillus subtilis (SEQ ID NO: 116) in yeast. "2μ ori" denotes a yeast origin of replication from the 2μ circle plasmid; "pMBl ori" denotes the E.coli pMBl origin of replication from the pBR322 plasmid; "AmpR" denotes the bla gene used as marker for selection with ampicillin; "PR11" denotes the S. cerevisiae FBA1 promoter -822 to -1; "NG4" denotes the Escherichia coli hph gene used as marker for selection with hygromycin; "TER6" denotes the S. cerevisiae FBA1 terminator 205 bp after stop; "PR4" denotes the Y.lipolytica EXP1 promoter -999 to -1 ; "NG321" denotes the native Bacillus subtilis subsp. subtilis 168 PTA cDNA synthetized by Life Technologies (SEQ ID

NO: 116); "TER1" denotes the Y.lipolytica CYC1 terminator 300 bp after stop; "Sc URA3" denotes the S. cerevisiae URA3 auxotrophic marker for selection in yeast.

Figure 8 is a graph that shows the absorbance at 412 nm for assays performed by incubating cell extracts with acetyl-CoA and DTNB. Cell extracts labeled NG321, NG322, NG324, NG309, NG310, and NG311 are cell extracts from Saccharomyces cerevisiae that each contain a gene for phosphate acetyltransferase, which can convert acetyl-CoA to CoA- SH, allowing CoA-SH to react with DTNB to produce the reporter molecule 5-thio-2- nitrobenzoate. The cell extract labeled NG306 is a cell extract from Saccharomyces cerevisiae comprising the phosphoketolase gene from Trichoderma reesei as a negative control.

Figure 9 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Saccharomyces cerevisiae that contain a gene for phosphate acetyltransferase, and for a negative control Saccharomyces cerevisiae strain NS20.

Figure 10 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Saccharomyces cerevisiae that contain a gene for phosphate acetyltransferase, and for a negative control Saccharomyces cerevisiae strain NS20.

Figure 11 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Arxula adeninivorans that contain a gene for phosphate acetyltransferase, and for negative control Arxula adeninivorans strains that each contain a gene for a

phosphoketolase (NG304 and NG306).

Figure 12 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Arxula adeninivorans that contain a gene for phosphate acetyltransferase, and for a negative control Arxula adeninivorans strain NS252.

Figure 13 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Yarrowia lipolytica that contain a gene for phosphate acetyltransferase, and for a negative control Yarrowia lipolytica strain NS18.

Figure 14 is a graph that shows specific phosphate acetyltransferase activity for cell extracts from Yarrowia lipolytica that contain a gene for phosphate acetyltransferase, and for a negative control Yarrowia lipolytica strain NS18.

Figure 15 is a map of the pNC468 construct, used to amplify knockout cassettes SEQ ID NO: 143 and SEQ ID NO: 144 to delete the PFK1 gene in Yarrowia lipolytica strain NS18. "2μ ori" denotes the S. cerevisiae origin of replication from the 2μ circle plasmid; "pMBl ori" denotes the E.coli pMBl origin of replication from the pBR322 plasmid;

"AmpR" denotes the bla gene used as marker for selection with ampicillin; "PR22" denotes the S. cerevisiae TEF1 promoter -412 to -1; "NG3" denotes the Streptomyces noursei Nat gene used as marker for selection with Nourseothricin; "TER2" denotes the S. cerevisiae CYC1 terminator 275 bp after stop; "PR1" denotes the Y. lipolytica TEF1 promoter -406 to - 1; "NG341" denotes the Herpes Simplex Virus TDK gene cDNA synthetized by Genscript; "TER7" denotes the Y.lipolytica TEF1 terminator 400 bp after stop; "Sc URA3" denotes the S. cerevisiae URA3 auxotrophic marker for selection in yeast. Figure 16 consists of two panels, labeled panels (A) and (B). The two panels show imaged DNA gels comprising PCR products from PCR performed on Y. lipolytica strains transformed with knockout cassettes corresponding to SEQ ID NO: 143 and SEQ ID NO: 144. Additionally, PCR products from the parent Y. lipolytica strain NS18 were analyzed a control. Panel (A) (top) shows results obtained from PCR performed with primers NP2784 (SEQ ID NO: 157) and NP2785 (SEQ ID NO: 158), which were used to assess whether a Y. lipolytica colony possesses an intact PFK1 gene. Only the negative control NS18 shows a band corresponding to a NP2784/NP2785 PCR product. Panel (B) (bottom) shows results obtained from PCR performed with primers NP2784 (SEQ ID NO: 157) and NP356 (SEQ ID NO: 152), which were used to assess whether a Y. lipolytica colony comprised a knockout cassette integrated into the Y. lipolytica genome at the PFK1 gene locus. Colonies 1, 2, 3, 5, 7, and 8 each displayed bands corresponding to a

NP2784/NP356 gene product. Colony 1 is named strain NS807.

Figure 17 is an image of Yarrowia lipolytica strain NS18, a wild type strain, and NS807, a strain transformed with knockout cassettes corresponding to SEQ ID NO: 143 and SEQ ID NO: 144. The strains were grown on plates comprising minimal media with glucose as the only carbon source. Strain NS18 was able to grow on glucose whereas strain NS807, which was engineered to delete phosphofructokinase 1, did not grow on glucose.

Figure 18 is a graph showing the specific phosphofructokinase activity of wild type Yarrowia lipolytica strain NS18 and knockout strain NS807.

DETAILED DESCRIPTION

Overview

In some aspects, the invention relates to the production of lipids {e.g., neutral lipids and triacylglycerols) in oleaginous yeasts, such as Yarrowia lipolytica and Arxula adeninivorans. In some aspects, the invention relates to a transformed cell comprising one or more genetic modifications that increase the yield of lipid from glucose in the cell relative to an unmodified cell of the same type. In some aspects, the invention relates to methods of increasing the lipid content of a cell by transforming the cell with one or more nucleotide sequences encoding proteins that increase the yield of lipid from glucose in the cell relative to an unmodified cell of the same type.

In some aspects, the invention relates to a transformed cell comprising one or more metabolically engineered pathways that more efficiently produce a metabolic precursor used to synthesize lipid molecules, e.g., acetyl co-enzyme A (acetyl-CoA), reduced nicotinamide adenine dinucleotide phosphate (NADPH), NADH, and adenosine

triphosphate (ATP), relative to unmodified cells of the same type. In some aspects, the invention relates to methods of increasing the lipid content of a cell by transforming the cell with one or more nucleotide sequences that encode proteins that catalyze or otherwise accomplish one or more steps in a metabolic pathway that produces a metabolic precursor, e.g., acetyl-CoA, NADPH, NADH, or ATP.

Pyruvate oxidation within the mitochondria and the export of acetyl-CoA via the metabolic intermediate citrate from the mitochondria to the cytosol results in net accumulation of NADH in the mitochondrion (Figure 1). This accumulation is unfavorable for obtaining high cellular lipid contents as reducing equivalents {e.g., NADH and

NADPH) must be available in the cytosol for the reduction of the acetyl group to an acyl group on the growing fatty acid chain. The preferred electron carrier for this reduction is NADPH, localized to the cytoplasm. In some aspects, the invention relates to a

transformed cell comprising one or more genetic modifications that increase the NADPH production {e.g., cytosolic NADPH production) in the cell relative to an unmodified cell of the same type. In some aspects, the invention relates to methods of increasing the lipid content of a cell by transforming the cell with one or more nucleotide sequences encoding proteins that increase the NADPH production {e.g., cytosolic NADPH production) in the cell relative to an unmodified cell of the same type. In some aspects, the invention relates to transformed cells comprising one or more genetic modifications that increase the utilization of cytosolic NADH and/or cytosolic NADPH in lipid production relative to an unmodified cell of the same type. In some aspects, the invention relates to methods of increasing the lipid content of a cell by transforming the cell with one or more nucleotide sequences encoding proteins that increase the utilization of cytosolic NADH and/or cytosolic NADPH in lipid production.

Definitions

The articles "a" and "an" are used herein to refer to one or to more than one {i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

The term "activity" refers to the total capacity of a cell to perform a function. For example, a genetic modification that decreases the activity of an enzyme in a cell may reduce the amount of the enzyme in a cell or reduce the efficiency of the enzyme. A knockout reduces the activity of a protein by reducing the amount of the protein in the cell. Alternatively, a mutation to a gene may reduce the efficiency of its protein product with little effect on the amount of the protein in the cell. Mutations that reduce the efficiency of an enzyme may affect the active site, for example, by changing one or more active site residues; they may impair the enzyme's kinetics, for example, by sterically blocking substrates or products; they may affect protein folding or dynamics, for example, by reducing the proportion of properly-folded enzymes; they may affect protein localization, for example, by preventing the protein from localizing to lipid particles; or they may affect protein degradation, for example, by adding one or more protein cleavage sites or by adding one or more residues or amino acid sequences that target the protein for proteolysis. These mutations affect coding regions. Mutations that decrease the activity of a protein may instead affect the transcription or translation of the gene. For example, mutation of an enhancer or promoter can reduce the activity of a protein by reducing its expression.

Mutating or deleting the non-coding portions of a gene, such as its introns, may also reduce transcription or translation. Additionally, mutations to the upstream regulators of a gene may affect the activity of its protein product; for example, the over-expression of one or more repressors may decrease the activity of a protein, and a knockout or mutation of one or more activators may similarly decrease the activity of a protein.

A genetic modification that increases the activity of a protein in a cell may increase the amount of the protein in the cell or increase the efficiency of the protein (e.g., the efficiency of an enzyme). For example, the genetic modification may simply insert an additional copy of the protein into the cell such that the additional copy is transcribed and translated into additional functional protein. The added gene can be native to the host organism or from a different organism. Alternatively, mutating or deleting the non-coding portions of a gene, such as its introns, may also increase translation. A native gene can be altered by adding a new promoter that causes more transcription. Similarly, enhancers may be added to the gene to increase transcription, or silencers may be mutated or deleted from the gene to increase transcription. Mutations to a native gene' s coding region might also increase the activity of the protein, for example, by producing a protein variant that does not interact with inhibitory proteins or molecules. The over-expression of one or more activators may increase the activity of a protein by increasing the expression of the protein, and a knockout or mutation of one or more repressors may similarly increase the activity of the protein. The term "biologically-active portion" refers to an amino acid sequence that is less than a full-length amino acid sequence, but exhibits at least one activity of the full length sequence. For example, a biologically-active portion of a phosphoketolase may refer to one or more domains of a phosphoketolase having biological activity for converting xylulose - 5-phosphate to glyceraldehyde-3 -phosphate. Biologically-active portions of a protein include peptides or polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein, e.g., the amino acid sequence set forth in SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 121, 123, or 125, which include fewer amino acids than the full length protein, and exhibit at least one activity of the protein. Similarly, biologically-active portions of a protein include peptides or polypeptides comprising amino acid sequences sufficiently identical to or derived from the amino acid sequence of the protein, e.g., an amino acid sequence set forth in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 121, 123, or 125, which include fewer amino acids than the full length protein, and exhibit at least one activity of the protein. A biologically-active portion of a protein may comprise, for example, at least 100,

425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700 or more amino acids. Typically, biologically-active portions comprise a domain or motif having a catalytic activity, such as catalytic activity for producing a molecule in a fatty acid biosynthesis pathway, or having a transporter activity, such as for mitochondrial transport. A biologically-active portion of a protein includes portions of the protein that have the same activity as the full-length peptide and every portion that has more activity than background. For example, a biologically-active portion of an enzyme may have 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 100%, 100.1%, 100.2%, 100.3%, 100.4%, 100.5%, 100.6%, 100.7%, 100.8%, 100.9%, 101%,

105%, 110%, 115%, 120%, 125%, 130%, 135%, 140%, 145%, 150%, 160%, 170%, 180%, 190%, 200%, 220%, 240%, 260%, 280%, 300%, 320%, 340%, 360%, 380%, 400% or higher activity relative to the full-length enzyme. A biologically-active portion of a protein may include portions of a protein that lack a domain that targets the protein to a cellular compartment. A biologically active portion of a phosphate acetyltransferase protein can be a polypeptide which is, for example, 310 amino acids in length.

The term domain refers to a part of the amino acid sequence of a protein that is able to fold into a stable three-dimensional structure independent of the rest of the protein. The term "drug refers to any molecule that inhibits cell growth or proliferation, thereby providing a selective advantage to cells that contain a gene that confers resistance to the drug. Drugs include antibiotics, antimicrobials, toxins, and pesticides.

"Dry weight" and "dry cell weight" mean weight determined in the relative absence of water. For example, reference to oleaginous cells as comprising a specified percentage of a particular component by dry weight means that the percentage is calculated based on the weight of the cell after substantially all water has been removed.

The term "encode" refers to nucleic acids that comprise a coding region, portion of a coding region, or compliments thereof. Both DNA and RNA may encode a gene. Both DNA and RNA may encode a protein.

The term "enzyme" as used herein refers to a protein that can catalyze a chemical reaction.

The term "exogenous" refers to anything that is introduced into a cell. An

"exogenous nucleic acid' is a nucleic acid that entered a cell through the cell membrane. An exogenous nucleic acid may contain a nucleotide sequence that exists in the native genome of a cell and/or nucleotide sequences that did not previously exist in the cell's genome. Exogenous nucleic acids include exogenous genes. An " exogenous gene" is a nucleic acid that codes for the expression of an RNA and/or protein that has been introduced into a cell {e.g., by transformation/transfection), and is also referred to as a "transgene." A cell comprising an exogenous gene may be referred to as a recombinant cell, into which additional exogenous gene(s) may be introduced. The exogenous gene may be from the same or different species relative to the cell being transformed. Thus, an exogenous gene can include a native gene that occupies a different location in the genome of the cell or is under different control, relative to the endogenous copy of the gene. An exogenous gene may be present in more than one copy in the cell. An exogenous gene may be maintained in a cell as an insertion into the genome (nuclear or plastid) or as an episomal molecule.

The term "expression" refers to the amount of a nucleic acid or amino acid sequence {e.g., peptide, polypeptide, or protein) in a cell. The increased expression of a gene refers to the increased transcription of that gene. The increased expression of an amino acid sequence, peptide, polypeptide, or protein refers to the increased translation of a nucleic acid encoding the amino acid sequence, peptide, polypeptide, or protein. The term "gene " as used herein, may encompass genomic sequences that contain exons, particularly polynucleotide sequences encoding polypeptide sequences involved in a specific activity. The term further encompasses synthetic nucleic acids that did not derive from genomic sequence. In certain embodiments, the genes lack introns, as they are synthesized based on the known DNA sequence of cDNA and protein sequence. In other embodiments, the genes are synthesized, non-native cDNA wherein the codons have been optimized for expression in Y. lipolytica based on codon usage. The term can further include nucleic acid molecules comprising upstream, downstream, and/or intron nucleotide sequences.

The term "genetic modification" refers to the result of a transformation. Every transformation causes a genetic modification by definition.

The term "homolog", as used herein, refers to (a) peptides, oligopeptides, polypeptides, proteins, and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified protein in question and having similar biological and functional activity as the unmodified protein from which they are derived, and (b) nucleic acids which encode peptides, oligopeptides, polypeptides, proteins, and enzymes with the same characteristics described in (a).

"Inducible promoter" is a promoter that mediates the transcription of an operably linked gene in response to a particular stimulus.

The term "integrated' refers to a nucleic acid that is maintained in a cell as an insertion into the cell's genome, such as insertion into a chromosome, including insertions into a plastid genome.

"In operable linkage" refers to a functional linkage between two nucleic acid sequences, such a control sequence (typically a promoter) and the linked sequence

(typically a sequence that encodes a protein, also called a coding sequence). A promoter is in operable linkage with a gene if it can mediate transcription of the gene.

The term "knockout mutation" or "knockout" refers to a genetic modification that prevents a native gene from being transcribed and translated into a functional protein.

The term "native" refers to the composition of a cell or parent cell prior to a transformation event. A "native gene" refers to a nucleotide sequence that encodes a protein that has not been introduced into a cell by a transformation event. A "native protein" refers to an amino acid sequence that is encoded by a native gene. The terms "nucleic acid" refers to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure, and may perform any function. The following are non-limiting examples of polynucleotides: coding or non-coding regions of a gene or gene fragment, loci (locus) defined from linkage analysis, exons, introns, messenger RNA

(mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes, and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. A polynucleotide may be further modified, such as by conjugation with a labeling component. In all nucleic acid sequences provided herein, U nucleotides are

interchangeable with T nucleotides.

The acronym "OR ' stands for open reading frame.

The term "parent celF refers to every cell from which a cell descended. The genome of a cell is comprised of the parent cell's genome and any subsequent genetic modifications to parent the cell's genome.

As used herein, the term "plasmid" refers to a circular DNA molecule that is physically separate from an organism's genomic DNA. Plasmids may be linearized before being introduced into a host cell (referred to herein as a linearized plasmid). Linearized plasmids may not be self-replicating, but may integrate into and be replicated with the genomic DNA of an organism.

The term "portion" refers to peptides, oligopeptides, polypeptides, protein domains, and proteins. A nucleotide sequence encoding a "portion of a protein" includes both nucleotide sequences that can be transcribed and/or translated and nucleotide sequences that must undergo one or more recombination events to be transcribed and/or translated. For example, a nucleic acid may comprise a nucleotide sequence encoding one or more amino acids of a selectable marker protein. This nucleic acid can be engineered to recombine with one or more different nucleotide sequences that encode the remaining portion of the protein. Such nucleic acids are useful for generating knockout mutations because only

recombination with the target sequence is likely to reconstitute the full-length selectable marker gene whereas random-integration events are unlikely to result in a nucleotide sequence that can produce a functional marker protein. A "promoter" is a nucleic acid control sequence that directs the transcription of a nucleic acid. As used herein, a promoter includes the necessary nucleic acid sequences near the start site of transcription. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.

The term "protein" refers to molecules that comprise an amino acid sequence, wherein the amino acids are linked by peptide bonds.

"Recombinant" refers to a cell, nucleic acid, protein, or vector, which has been modified due to the introduction of an exogenous nucleic acid or the alteration of a native nucleic acid. Thus, e.g., recombinant cells can express genes that are not found within the native (non-recombinant) form of the cell or express native genes differently than those genes are expressed by a non-recombinant cell. Recombinant cells can, without limitation, include recombinant nucleic acids that encode for a gene product or for suppression elements such as mutations, knockouts, antisense, interfering RNA (RNAi), or dsRNA that reduce the levels of active gene product in a cell. A "recombinant nucleic acid" is a nucleic acid originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases, ligases, exonucleases, and endonucleases, or otherwise is in a form not normally found in nature. Recombinant nucleic acids may be produced, for example, to place two or more nucleic acids in operable linkage. Thus, an isolated nucleic acid or an expression vector formed in vitro by ligating DNA molecules that are not normally joined in nature, are both considered recombinant for the purposes of this invention. Once a recombinant nucleic acid is made and introduced into a host cell or organism, it may replicate using the in vivo cellular machinery of the host cell; however, such nucleic acids, once produced recombinantly, although subsequently replicated intracellularly, are still considered recombinant for purposes of this invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e., through the expression of a

recombinant nucleic acid.

The term "regulatory region" refers to nucleotide sequences that affect the transcription or translation of a gene but do not encode an amino acid sequence. Regulatory regions include promoters, operators, enhancers, and silencers.

The term "substantially identicaF refers to a nucleotide or amino acid sequence that encodes a biologically-active portion of a protein, which has 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%), 99.6%), 99.7%), 99.8%, 99.9% or more sequence identity with a reference sequence. For enzymes, a substantially identical sequence typically retains the enzymatic activity of the reference sequence. For example, a sequence is substantially identical to a reference sequence if it encodes an enzyme that has between 10%> and 1,000%> of the enzymatic activity of the reference enzyme.

"Transformation" refers to the transfer of a nucleic acid into a host organism or the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "recombinant", "transgenic" or "transformed" organisms. Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. Typically, expression vectors include, for example, one or more cloned genes under the transcriptional control of 5' and 3' regulatory sequences and a selectable marker. Such vectors also can contain a promoter regulatory region {e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or location-specific expression), a transcription initiation start site, a ribosome binding site, a transcription termination site, and/or a polyadenylation signal.

The term "transformed celF refers to a cell that has undergone a transformation. Thus, a transformed cell comprises the parent's genome and an inheritable genetic modification.

The terms "triacylglyceride " "triacylglycerol " triglyceride " and "TAG" are esters comprised of glycerol and three fatty acids.

The term "vector" refers to the means by which a nucleic acid can be propagated and/or transferred between organisms, cells, or cellular components. Vectors include plasmids, linear DNA fragments, viruses, bacteriophage, pro-viruses, phagemids, transposons, and artificial chromosomes, and the like, that may or may not be able to replicate autonomously or integrate into a chromosome of a host cell. Microbe Engineering

A. Overview

In certain embodiments of the invention, a microorganism is genetically modified to increase its lipid content.

Genes and gene products may be introduced into microbial host cells. Suitable host cells for expression of the genes and nucleic acid molecules are microbial hosts that can be found broadly within the fungal or bacterial families. Examples of suitable host strains include but are not limited to fungal or yeast species, such as Arxula, Aspegillus,

Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Leucosporidiella, Lipomyces, Mortierella,

Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces, and Yarrow ia, or bacterial species, such as members of proteobacteria and actinomycetes, as well as the genera Acinetobacter, Arthrobacter, Brevibacterium, Acidovorax, Bacillus, Clostridia, Streptomyces, Escherichia, Salmonella, Pseudomonas, and Cornyebacterium. Yarrowia lipolytica and Arxula adeninivorans are suited for use as a host microorganism because they can accumulate a large percentage of their weight as triacylglycerols.

Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are known to those skilled in the art. Any of these could be used to construct chimeric genes to produce any one of the gene products of the instant sequences. These chimeric genes could then be introduced into appropriate microorganisms via transformation techniques to provide high-level expression of the enzymes.

For example, a gene encoding an enzyme can be cloned in a suitable plasmid, and an aforementioned starting parent strain as a host can be transformed with the resulting plasmid. This approach can increase the copy number of each of the genes encoding the enzymes and, as a result, the activities of the enzymes can be increased. The plasmid is not particularly limited so long as it renders a desired genetic modification inheritable to the microorganism's progeny.

Vectors or cassettes useful for the transformation of suitable host cells are well known in the art. Typically the vector or cassette contains sequences that direct the transcription and translation of the relevant gene, a selectable marker, and sequences that allow autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene harboring transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is preferred when both control regions are derived from genes homologous to the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.

Promoters, cDNAs, and 3'UTRs, as well as other elements of the vectors, can be generated through cloning techniques using fragments isolated from native sources (Green & Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., 2012); U.S. Patent No. 4,683,202; incorporated by reference). Alternatively, elements can be generated synthetically using known methods (Gene 164:49-53 (1995)).

B. Homologous Recombination

Homologous recombination is the ability of complementary DNA sequences to align and exchange regions of homology. Transgenic DNA ("donor") containing sequences homologous to the genomic sequences being targeted ("template") is introduced into the organism and then undergoes recombination into the genome at the site of the

corresponding homologous genomic sequences.

The ability to carry out homologous recombination in a host organism has many practical implications for what can be carried out at the molecular genetic level and is useful in the generation of a microbe that can produce a desired product. By its nature homologous recombination is a precise gene targeting event and, hence, most transgenic lines generated with the same targeting sequence will be essentially identical in terms of phenotype, necessitating the screening of far fewer transformation events. Homologous recombination also targets gene insertion events into the host chromosome, potentially resulting in excellent genetic stability, even in the absence of genetic selection. Because different chromosomal loci will likely impact gene expression, even from exogenous promoters/UTRs, homologous recombination can be a method of querying loci in an unfamiliar genome environment and to assess the impact of these environments on gene expression.

A particularly useful genetic engineering approach using homologous recombination is to co-opt specific host regulatory elements, such as promoters/UTRs, to drive

heterologous gene expression in a highly specific fashion.

Because homologous recombination is a precise gene targeting event, it can be used to precisely modify any nucleotide(s) within a gene or region of interest, so long as sufficient flanking regions have been identified. Therefore, homologous recombination can be used as a means to modify regulatory sequences impacting gene expression of RNA and/or proteins. It can also be used to modify protein coding regions in an effort to modify enzyme activities such as substrate specificity, affinities and Km, thereby affecting a desired change in the metabolism of the host cell. Homologous recombination provides a powerful means to manipulate the host genome resulting in gene targeting, gene conversion, gene deletion, gene duplication, gene inversion, and exchanging gene expression regulatory elements such as promoters, enhancers and 3'UTRs.

Homologous recombination can be achieved by using targeting constructs containing pieces of endogenous sequences to "target" the gene or region of interest within the endogenous host cell genome. Such targeting sequences can either be located 5' of the gene or region of interest, 3' of the gene/region of interest or even flank the gene/region of interest. Such targeting constructs can be transformed into the host cell either as a supercoiled plasmid DNA with additional vector backbone, a PCR product with no vector backbone, or as a linearized molecule. In some cases, it may be advantageous to first expose the homologous sequences within the transgenic DNA (donor DNA) by cutting the transgenic DNA with a restriction enzyme. This step can increase the recombination efficiency and decrease the occurrence of undesired events. Other methods of increasing recombination efficiency include using PCR to generate transforming transgenic DNA containing linear ends homologous to the genomic sequences being targeted.

C. Vectors and Vector Components

Vectors for transforming microorganisms in accordance with the present invention can be prepared by known techniques familiar to those skilled in the art in view of the disclosure herein. A vector typically contains one or more genes, in which each gene codes for the expression of a desired product (the gene product) and is operably linked to one or more control sequences that regulate gene expression or target the gene product to a particular location in the recombinant cell.

1. Control Sequences

Control sequences are nucleic acids that regulate the expression of a coding sequence or direct a gene product to a particular location in or outside a cell. Control sequences that regulate expression include, for example, promoters that regulate transcription of a coding sequence and terminators that terminate transcription of a coding sequence. Another control sequence is a 3' untranslated sequence located at the end of a coding sequence that encodes a polyadenylation signal. Control sequences that direct gene products to particular locations include those that encode signal peptides, which direct the protein to which they are attached to a particular location inside or outside the cell.

Thus, an exemplary vector design for expression of a gene in a microbe contains a coding sequence for a desired gene product (for example, a selectable marker, or an enzyme) in operable linkage with a promoter active in yeast. Alternatively, if the vector does not contain a promoter in operable linkage with the coding sequence of interest, the coding sequence can be transformed into the cells such that it becomes operably linked to an endogenous promoter at the point of vector integration.

The promoter used to express a gene can be the promoter naturally linked to that gene or a different promoter.

A promoter can generally be characterized as constitutive or inducible. Constitutive promoters are generally active or function to drive expression at all times (or at certain times in the cell life cycle) at the same level. Inducible promoters, conversely, are active (or rendered inactive) or are significantly up- or down-regulated only in response to a stimulus. Both types of promoters find application in the methods of the invention.

Inducible promoters useful in the invention include those that mediate transcription of an operably linked gene in response to a stimulus, such as an exogenously provided small molecule, temperature (heat or cold), lack of nitrogen in culture media, etc. Suitable promoters can activate transcription of an essentially silent gene or upregulate transcription of an operably linked gene that is transcribed at a low level.

Inclusion of termination region control sequence is optional, and if employed, then the choice is primarily one of convenience, as the termination region is relatively interchangeable. The termination region may be native to the transcriptional initiation region (the promoter), may be native to the DNA sequence of interest, or may be obtainable from another source {See, e.g., Chen & Orozco, Nucleic Acids Research 7(5:8411 (1988)).

2. Genes and Codon Optimization

Typically, a gene includes a promoter, a coding sequence, and termination control sequences. When assembled by recombinant DNA technology, a gene may be termed an expression cassette and may be flanked by restriction sites for convenient insertion into a vector that is used to introduce the recombinant gene into a host cell. The expression cassette can be flanked by DNA sequences from the genome or other nucleic acid target to facilitate stable integration of the expression cassette into the genome by homologous recombination. Alternatively, the vector and its expression cassette may remain

unintegrated (e.g., an episome), in which case, the vector typically includes an origin of replication, which is capable of providing for replication of the vector DNA.

A common gene present on a vector is a gene that codes for a protein, the expression of which allows the recombinant cell containing the protein to be differentiated from cells that do not express the protein. Such a gene, and its corresponding gene product, is called a selectable marker or selection marker. Any of a wide variety of selectable markers can be employed in a transgene construct useful for transforming the organisms of the invention.

For optimal expression of a recombinant protein, it is beneficial to employ coding sequences that produce mRNA with codons optimally used by the host cell to be transformed. Thus, proper expression of transgenes can require that the codon usage of the transgene matches the specific codon bias of the organism in which the transgene is being expressed. The precise mechanisms underlying this effect are many, but include the proper balancing of available aminoacylated tRNA pools with proteins being synthesized in the cell, coupled with more efficient translation of the transgenic messenger RNA (mRNA) when this need is met. When codon usage in the transgene is not optimized, available tRNA pools are not sufficient to allow for efficient translation of the transgenic mRNA resulting in ribosomal stalling and termination and possible instability of the transgenic mRNA.

C. Transformation

Cells can be transformed by any suitable technique including, e.g., biolistics, electroporation, glass bead transformation, and silicon carbide whisker transformation.

Any convenient technique for introducing a transgene into a microorganism can be employed in the present invention. Transformation can be achieved by, for example, the method of D. M. Morrison (Methods in Enzymology 68:326 (1979)), the method by increasing permeability of recipient cells for DNA with calcium chloride (Mandel & Higa,

J. Molecular Biology, 53: 159 (1970)), or the like.

Examples of expression of transgenes in oleaginous yeast (e.g., Yarrowia lipolytica) can be found in the literature (Bordes et al., J. Microbiological Methods, 70:493 (2007); Chen et al., Applied Microbiology & Biotechnology ¥5:232 (1997)). Examples of expression of exogenous genes in bacteria such as E. coli are well known (Green &

Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., 2012)). Vectors for transformation of microorganisms in accordance with the present invention can be prepared by known techniques familiar to those skilled in the art. In one embodiment, an exemplary vector design for expression of a gene in a microorganism contains a gene encoding an enzyme in operable linkage with a promoter active in the microorganism. Alternatively, if the vector does not contain a promoter in operable linkage with the gene of interest, the gene can be transformed into the cells such that it becomes operably linked to a native promoter at the point of vector integration. The vector can also contain a second gene that encodes a protein. Optionally, one or both gene(s) is/are followed by a 3' untranslated sequence containing a polyadenylation signal. Expression cassettes encoding the two genes can be physically linked in the vector or on separate vectors. Co-transformation of microbes can also be used, in which distinct vector molecules are simultaneously used to transform cells (Protist 755:381-93 (2004)). The transformed cells can be optionally selected based upon the ability to grow in the presence of the antibiotic or other selectable marker under conditions in which cells lacking the resistance cassette would not grow.

D. Nucleic acids and methods of increasing the activity of a protein

The genes of the invention may comprise conservative substitutions, deletions, and/or insertions while still encoding a protein that has activity. For example, codons may be optimized for a particular host cell, different codons may be substituted for convenience, such as to introduce a restriction site or to create optimal PCR primers, or codons may be substituted for another purpose. Similarly, the nucleotide sequence may be altered to create conservative amino acid substitutions, deletions, and/or insertions.

Proteins may comprise conservative substitutions, deletions, and/or insertions while still maintaining activity. Conservative substitution tables are well known in the art (Creighton, Proteins (2d. ed., 1992)).

Amino acid substitutions, deletions and/or insertions may readily be made using recombinant DNA manipulation techniques. Methods for the manipulation of DNA sequences to produce substitution, insertion or deletion variants of a protein are well known in the art. These methods include Ml 3 mutagenesis, T7-Gen in vitro mutagenesis (USB, Cleveland, OH), Quick Change Site Directed mutagenesis (Stratagene, San Diego, CA), PCR-mediated site-directed mutagenesis, and other site-directed mutagenesis protocols.

To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences can be aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second amino acid or nucleic acid sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). The length of a reference sequence aligned for comparison purposes can be at least 95% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions can then be compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid or nucleic acid "identity" is equivalent to amino acid or nucleic acid "homology"). The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. In one embodiment, the percent identity between two amino acid sequences can be determined using the Needleman and Wunsch (J. Molecular Biology ¥5:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at

http://www.gcg.com), using either a Blosum 62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another embodiment, the percent identity between two nucleotide sequences can be determined using the GAP program in the GCG software package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4, 5, or 6. In another embodiment, the percent identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller (Computer Applications in the Biosciences 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0 or 2.0U), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.

Exemplary computer programs which can be used to determine identity between two sequences include, but are not limited to, the suite of BLAST programs, e.g., BLASTN, MEGABLAST, BLASTX, TBLASTN, TBLASTX, and BLASTP, and Clustal programs, e.g., ClustalW, ClustalX, and Clustal Omega.

Sequence searches are typically carried out using the BLASTN program, when evaluating a given nucleic acid sequence relative to nucleic acid sequences in the GenBank DNA Sequences and other public databases. The BLASTX program is effective for searching nucleic acid sequences that have been translated in all reading frames against amino acid sequences in the GenBank Protein Sequences and other public databases.

An alignment of selected sequences in order to determine "% identity" between two or more sequences is performed using for example, the CLUSTAL-W program.

A "coding sequence" or "coding region" refers to a nucleic acid molecule having sequence information necessary to produce a protein product, such as an amino acid or polypeptide, when the sequence is expressed. The coding sequence may comprise and/or consist of untranslated sequences (including introns or 5' or 3' untranslated regions) within translated regions, or may lack such intervening untranslated sequences (e.g., as in cDNA).

The abbreviation used throughout the specification to refer to nucleic acids comprising and/or consisting of nucleotide sequences are the conventional one-letter abbreviations. Thus when included in a nucleic acid, the naturally occurring encoding nucleotides are abbreviated as follows: adenine (A), guanine (G), cytosine (C), thymine (T) and uracil (U). Also, unless otherwise specified, the nucleic acid sequences presented herein is the 5'→3' direction.

As used herein, the term "complementary" and derivatives thereof are used in reference to pairing of nucleic acids by the well-known rules that A pairs with T or U and C pairs with G. Complement can be "partial" or "complete". In partial complement, only some of the nucleic acid bases are matched according to the base pairing rules; while in complete or total complement, all the bases are matched according to the pairing rule. The degree of complement between the nucleic acid strands may have significant effects on the efficiency and strength of hybridization between nucleic acid strands as well known in the art. The efficiency and strength of said hybridization depends upon the detection method.

Amino acid and nucleotide sequences may be derived from oleaginous organisms having high, native levels of lipid accumulation. (Bioresource Technology 144:360-69 (2013); Progress Lipid Research 52:395-408 (2013); Applied Microbiology &

Biotechnology 90: 1219-27 (2011); European Journal Lipid Science & Technology

773: 1031-51 (2011); Food Technology & Biotechnology ¥7:215-20 (2009); Advances Applied Microbiology 57: 1-51 (2002); Lipids 77:837-44 (1976)). A list of organisms with a reported lipid content of about 50% and higher is shown in Table 1. R. toruloides and L. starkeyi have the highest lipid content. Table 1

List of oleaginous fungi with reported lipid contents of about 50% and above.

A protein's activity may be increased by overexpressing the protein. Proteins may be overexpressed in a cell using a variety of genetic modifications. In some embodiments, the genetic modification increases the expression of a native protein. A native protein may be overexpressed by modifying the upstream transcription regulators of the gene that encodes the protein, for example, by increasing the expression of a transcription activator or decreasing the expression of a transcription repressor. Alternatively, the promoter of a native gene may be substituted with a constitutively active or inducible promoter by recombination with an exogenous nucleic acid.

In some embodiments, a genetic modification that increases the activity of a protein comprises transformation with a nucleic acid that comprises a gene that encodes the protein. The gene may be native to the cell or from a different species. In certain embodiments, the gene is inheritable to the progeny of a transformed cell. In some embodiments, the gene is inheritable because it resides on a plasmid. In certain embodiments, the gene is inheritable because it is integrated into the genome of the transformed cell.

E. Nucleic acids and methods of decreasing the activity of a native protein

In some embodiments, the transformed oleaginous cell comprises a genetic modification that decreases the activity of a native protein. Such genetic modifications may affect a protein that regulates the transcription of the native protein, including modifications that decrease the expression of a transcription activator and/or increase the expression of a transcription repressor. Modifications that affect a regulator protein may both decrease the expression of the native protein and alter other gene expression profiles that shift the cellular equilibrium toward increased oleic acid accumulation. Alternatively, the genetic modification may be the introduction of an interfering nucleic acid, such as a small interfering RNA, or a nucleic acid that encodes an interfering nucleic acid. In other embodiments, the genetic modification consists of the homologous recombination of a nucleic acid and the regulatory region of a gene that encodes the native protein. The regulatory region of the gene may include an operator, promoter, sequences upstream from the promoter, enhancers, and/or sequences downstream of the gene.

In some embodiments the transformed oleaginous cell comprises a genetic modification consisting of a homologous recombination event. In certain embodiments, the transformed cell comprises a genetic modification consisting of a homologous

recombination event between a native gene and a nucleic acid. Thus, the genetic modification deletes the native gene, prevents its transcription, or prevents the transcription of a gene that can be translated into a fully-active protein. A homologous recombination event may mutate or delete a portion of a native gene. For example, the homologous recombination event may mutate one or more residues in the active site of a native enzyme, thereby reducing the efficiency of the enzyme or rendering it inactive. Alternatively, the homologous recombination event may affect post-translational modification, folding, stability, or localization within the cell. In some embodiments, the homologous recombination event replaces the promoter with a promoter that drives less transcription. In other embodiments, the homologous recombination event mutates the promoter to impair its ability to drive transcription. In certain embodiments, the genetic modification is a knockout mutation.

A knockout mutation may delete one or more genes. Additionally, the knockout mutation may substitute a native gene with an exogenous gene that encodes a different protein. The exogenous gene may be operably linked to an exogenous promoter. In certain embodiments, the gene is not linked to an exogenous promoter, and instead, the gene is configured to recombine with the native gene such that the native gene's promoter drives transcription of the exogenous gene. Thus, the gene is less likely to be expressed if it randomly integrates into the cell's genome. Methods for creating knockouts are well- known in the art {See, e.g., Fickers et al., J. Microbiological Methods 55:121 (2003)).

In certain embodiments, the genetic modification comprises two homologous recombination events. In the first event, a nucleic acid encoding a portion of a gene recombines with the native gene, and in the second event, a nucleic acid encoding the remaining portion of the gene recombines with the native gene. The two portions of the gene are designed such that neither portion is functional unless they recombine with each other. These two events further reduce the likelihood that the gene can be expressed following random integration events.

In certain embodiments, the gene encodes a marker protein, such as a dominant selectable marker. Thus, knockout cells may be selected by screening for the marker. In some embodiments, the dominant selectable marker is a drug resistance marker. A drug resistance marker is a dominant selectable marker that, when expressed by a cell, allows the cell to grow and/or survive in the presence of a drug that would normally inhibit cellular growth and/or survival. Cells expressing a drug resistance marker can be selected by growing the cells in the presence of the drug. In some embodiments, the drug resistance marker is an antibiotic resistance marker. In some embodiments, the drug resistance marker confers resistance to a drug selected from the group consisting of Amphotericin B, Candicidin, Filipin, Hamycin, Natamycin, Nystatin, Rimocidin, Bifonazole, Butoconazole, Clotrimazole, Econazole, Fenticonazole, Isoconazole, Ketoconazole, Luliconazole, Miconazole, Omoconazole, Oxiconazole, Sertaconazole, Sulconazole, Tioconazole, Albaconazole, Fluconazole, Isavuconazole, Itraconazole, Posaconazole, Ravuconazole, Terconazole, Voriconazole, Abafungin, Amorolfin, Butenafine, Naftifine, Terbinafine, Anidulafungin, Caspofungin, Micafungin, Benzoic acid , Ciclopirox, Flucytosine, 5- fluorocytosine, Griseofulvin, Haloprogin, Polygodial, Tolnaftate, Crystal violet, Amikacin, Gentamicin, Kanamycin, Neomycin, Netilmicin, Tobramycin, Paromomycin,

Spectinomycin, Geldanamycin, Herbimycin, Rifaximin, Streptomycin, Loracarbef, Ertapenem, Doripenem, Imipenem, Meropenem, Cefadroxil, Cefazolin, Cefalotin,

Cefalexin, Cefaclor, Cefamandole, Cefoxitin, Cefprozil, Cefuroxime, Cefixime, Cefdinir, Cefditoren, Cefoperazone, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftibuten,

Ceftizoxime, Ceftriaxone, Cefepime, Ceftaroline fosamil, Ceftobiprole, Teicoplanin, Vancomycin, Telavancin, Clindamycin, Lincomycin, Daptomycin, Azithromycin,

Clarithromycin, Dirithromycin, Erythromycin, Roxithromycin, Troleandomycin,

Telithromycin, Spiramycin, Aztreonam, Furazolidone, Nitrofurantoin, Linezolid, Posizolid, Radezolid, Torezolid, Amoxicillin, Ampicillin, Azlocillin, Carbenicillin, Cloxacillin, Dicloxacillin, Flucloxacillin, Mezlocillin, Methicillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Penicillin G, Temocillin, Ticarcillin, clavulanate, sulbactam, tazobactam, clavulanate, Bacitracin, Colistin, Polymyxin B, Ciprofloxacin, Enoxacin, Gatifloxacin, Levofloxacin, Lomefloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Ofloxacin, Trovafloxacin, Grepafloxacin, Sparfloxacin, Temafloxacin, Mafenide,

Sulfacetamide, Sulfadiazine, Silver sulfadiazine, Sulfadimethoxine, Sulfamethizole, Sulfamethoxazole, Sulfanamide, Sulfasalazine, Sulfisoxazole, Trimethoprim- Sulfamethoxazole, Co-trimoxazole, Sulfonamidochrysoidine, Demeclocycline,

Doxycycline, Minocycline, Oxytetracycline, Tetracycline, Clofazimine, Dapsone,

Capreomycin, Cycloserine, Ethambutol, Ethionamide, Isoniazid, Pyrazinamide,

Rifampicin , Rifabutin, Rifapentine, Streptomycin, Arsphenamine, Chloramphenicol, Fosfomycin, Fusidic acid, Metronidazole, Mupirocin, Platensimycin, Quinupristin, Dalfopristin, Thiamphenicol, Tigecycline, Tinidazole, Trimethoprim, Geneticin,

Nourseothricin, Hygromycin, Bleomycin, and Puromycin.

In some embodiments, the dominant selectable marker is a nutritional marker. A nutritional marker is a dominant selectable marker that, when expressed by the cell, enables the cell to grow or survive using one or more particular nutrient sources. Cells expressing a nutritional marker can be selected by growing the cells under limiting nutrient conditions in which cells expressing the nutritional marker can survive and/or grow, but cells lacking the nutrient marker cannot. In some embodiments, the nutritional marker is selected from the group consisting of Orotidine 5-phosphate decarboxylase, Phosphite specific oxidoreductase, Alpha-ketoglutarate-dependent hypophosphite dioxygenase, Alkaline phosphatase, Cyanamide hydratase, Melamine deaminase, Cyanurate amidohydrolase, Biuret hydrolyase, Urea amidolyase, Ammelide aminohydrolase, Guanine deaminase, Phosphodiesterase, Phosphotriesterase, Phosphite hydrogenase, Glycerophosphodiesterase, Parathion hydrolyase, Phosphite dehydrogenase, Dibenzothiophene desulfurization enzyme, Aromatic desulfinase, FMN reductase, NADH-dependent FMN reductase, Aminopurine transporter, Hydroxylamine oxidoreductase, Invertase, Beta-glucosidase, Alpha- glucosidase, Beta-galactosidase, Alpha-galactosidase, Amylase, Cellulase, and Pullulonase.

Different approaches may be used to knockout a gene in a yeast cell {See, e.g., Dulermo et al., Biochimica Biophysica Acta 7537: 1486 (2013)). The methods disclosed herein and other methods known in the art may be used to knockout different genes in other species, such as Arxula adeninivorans.

In some embodiments, a genetic modification decreases the expression of a native gene by 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9, or 100 percent.

In some embodiments, a genetic modification decreases the efficiency of a native protein by 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9, or 100 percent.

In some embodiments, a genetic modification decreases the activity of a native protein by 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9, or 100 percent.

Exemplary Cells. Nucleic Acids, and Methods

A. Transformed Cell

In some embodiments, the transformed cell is a prokaryotic cell, such as a bacterial cell. In some embodiments, the cell is a eukaryotic cell, such as a mammalian cell, a yeast cell, a filamentous fungi cell, a protist cell, an algae cell, an avian cell, a plant cell, or an insect cell. In some embodiments, the cell is a yeast. Those with skill in the art will recognize that many forms of filamentous fungi produce yeast-like growth, and the definition of yeast herein encompasses such cells. The cell may be selected from the group consisting of Arxula, Aspegillus,

Aurantiochytrium, Candida, Claviceps, Cryptococcus, Cunninghamella, Geotrichum, Hansenula, Kluyveromyces, Kodamaea, Leucosporidiella, Lipomyces, Mortierella,

Ogataea, Pichia, Prototheca, Rhizopus, Rhodosporidium, Rhodotorula, Saccharomyces, Schizosaccharomyces, Tremella, Trichosporon, Wickerhamomyces, and Yarrow ia.

In some embodiments, the cell is selected from the group of consisting of Arxula adeninivorans, Aspergillus niger, Aspergillus orzyae, Aspergillus terreus, Aurantiochytrium limacinum, Candida utilis, Claviceps purpurea, Cryptococcus albidus, Cryptococcus curvatus, Cryptococcus ramirezgomezianus, Cryptococcus terreus, Cryptococcus wieringae, Cunninghamella echinulata, Cunninghamella japonica, Geotrichum fermentans, Hansenula polymorpha, Kluyveromyces lactis, Kluyveromyces marxianus, Kodamaea ohmeri, Leucosporidiella creatinivora, Lipomyces lipofer, Lipomyces starkeyi, Lipomyces tetrasporus, Mortierella isabellina, Mortierella alpina, Ogataea polymorpha, Pichia ciferrii, Pichia guilliermondii, Pichia pastoris, Pichia stipites, Prototheca zopfii, Rhizopus arrhizus, Rhodosporidium babjevae, Rhodosporidium toruloides, Rhodosporidium paludigenum, Rhodotorula glutinis, Rhodotorula mucilaginosa, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Tremella enchepala, Trichosporon cutaneum, Trichosporon fermentans, Wickerhamomyces ciferrii, and Yarrowia lipolytica.

In certain embodiments, the cell is Saccharomyces cerevisiae, Yarrowia lipolytica, or Arxula adeninivorans. In certain embodiments, the cell is not Saccharomyces cerevisiae.

In some embodiments, the cell is a yeast, fungus, or yeast-like algae. The cell may be selected from thraustochytrids (Aurantiochytrium) and achlorophylic unicellular algae (Prototheca).

In certain embodiments, the transformed cell comprises at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%), 84%), 85%), or more lipid as measured by % dry cell weight.

B. Cells comprising phosphoketolase and phosphate acetyltransferase activity

Cells comprising phosphoketolase and phosphate acetyltransferase activity can catalyze the conversion of xylulose-5-phosphate to acetyl-CoA, which allows the cell to produce acetyl-CoA from glucose in the cytoplasm, thereby increasing cytosolic NADPH relative to cells that rely on the mitochondrial pathway (Figures 2 and 3). Three versions of phosphoketolase exist, those acting on the five carbon xylulose-5- phosphate (X-5-P), EC 4.1.2.9, those acting on the six carbon fructose-6-phosphate (F-6-P), EC 4.1.2.22, and those with bifunctional activity on both substrates. The 6-carbon phosphoketolase together with a transketolase (EC 2.2.1.1), which is present in all microorganisms, catalyze reactions with the same net conversion of xylulose-5-phosphate to acetyl phosphate (Ac-P) and glyceraldehyde-3 -phosphate (Ga-3-P) as the 5-carbon phosphoketolase. Transketolase coverts xylulose-5-phosphate (X-5-P) and erythrose-4- phosphate (E-4-P) to fructose-6-phosphate (F-6-P) and glyceraldehyde-3 -phosphate (Ga-3- P)

i) EC 4.1.2.9 X-5-P + Pi -> Ac-P + Ga-3-P + H20

ii) EC 4.1.2.22 F-6-P + Pi -> Ac-P + E-4-P + H20

EC 2.2.1.1 X-5-P + E-4-P -> F-6-P + Ga-3-P

Net: X-5-P + Pi -> Ac-P + Ga-3-P + H20

Methods of introducing genes that encode phosphoketolase and phosphate acetyltransferase proteins into a cell are known in the art {See, e.g., U.S. Patent Application Publication No. 2012/0156735; hereby incorporated by reference).

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, and a second genetic modification, wherein said first genetic modification increases the activity of a phosphoketolase protein in the cell, and said second genetic modification increases the activity of a phosphate acetyltransferase protein in the cell. In some embodiments, the transformed cell can catalyze the

phosphoketolase/phosphate acetyltransferase pathway described above. In some embodiments, the transformed cell does not catalyze a phosphoketolase/phosphate acetyltransferase pathway, e.g., the cell may utilize either the phosphoketolase and/or phosphate acetyltransferase proteins to convert xylulose-5-phosphate, fructose-6-phosphate, or different substrates {e.g., different sugars) into acetyl phosphate and glyceraldehyde-3 - phosphate or different products; or, e.g., the cell may serve as a host cell for molecular cloning.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a phosphoketolase protein, and transforming said cell with a second nucleotide sequence that encodes a phosphate acetyltransferase protein. The method may increase the lipid content of the cell by completing the phosphoketolase/phosphate acetyltransferase pathway described above. In some embodiments, the method increases the lipid content of the cell through a molecular pathway other than the phosphoketolase/phosphate

acetyltransferase pathway, e.g., the transformed cell may utilize either the phosphoketolase and/or phosphate acetyltransferase proteins to convert xylulose-5-phosphate, fructose-6- phosphate, or different substrates (e.g., different sugars) into acetyl phosphate and glyceraldehyde-3 -phosphate or different products. The phosphoketolase and/or phosphate acetyltransferase may catalyze steps in a different metabolic pathway, for example, such as a metabolic pathway that tends to increase lipid biosynthesis or decrease lipid degradation.

In some embodiments, the phosphoketolase protein is classified by Enzyme

Commission number EC 4.1.2.9 or EC 4.1.2.22.

The phosphoketolase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, or a biologically active portion of any one of them. For example, the phosphoketolase protein may be substantially identical to SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, and retain the functional activity of the protein of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID

NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the phosphoketolase protein comprises the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125.

The first genetic modification may be transformation with a first nucleic acid, and the first nucleic acid may encode a phosphoketolase protein, i.e., the first nucleic acid may comprise a first nucleotide sequence that encodes a phosphoketolase protein.

In some embodiments, the first nucleotide sequence has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO: 122, SEQ ID NO: 124, or SEQ ID NO: 126. For example, the first nucleotide sequence may have the sequence set forth in SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO: 122, SEQ ID NO: 124, or SEQ ID NO: 126. In some embodiments, the first nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO: 122, SEQ ID NO: 124, or SEQ ID NO: 126, and the first nucleotide sequence encodes a phosphoketolase protein that retains the activity of a protein encoded by SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, yet the first nucleotide sequence differs from the sequence set forth in SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO: 122, SEQ ID NO: 124, or SEQ ID NO: 126, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the first nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%), 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, or a biologically active portion of any one of them. For example, the first nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125. In some embodiments, the first nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, and the first nucleotide sequence encodes a phosphoketolase protein that retains the activity of a protein encoded by SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, yet the first nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO:21, SEQ ID

NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO: 121, SEQ ID NO: 123, or SEQ ID NO: 125, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the phosphate acetyltransferase protein is classified by Enzyme Commission number EC 2.3.1.8.

The phosphate acetyltransferase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:l, SEQIDNO:3, SEQIDNO:5, SEQIDNO:33, SEQIDNO:35, SEQIDNO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQIDNO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119 or a biologically active portion of any one of them. For example, the phosphate acetyltransferase protein may be substantially identical to SEQ ID NO:l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQIDNO:47, SEQIDNO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, and retain the functional activity of the protein of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the phosphate acetyltransferase protein comprises the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119.

The second genetic modification may be transformation with a second nucleic acid, and the second nucleic acid may encode a phosphate acetyltransferase protein, i.e., the second nucleic acid may comprise a second nucleotide sequence that encodes a phosphate acetyltransferase protein.

In some embodiments, the second nucleotide sequence has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%,

99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120. For example, the second nucleotide sequence may have the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120. In some embodiments, the second nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120, and the second nucleotide sequence encodes a phosphate acetyltransferase protein that retains the activity of a protein encoded by SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, yet the second nucleotide sequence differs from the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the second nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%), 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, or a biologically active portion of any one of them. For example, the second nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: l l l, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119. In some embodiments, the second nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39,

SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID N0:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID N0:91, SEQ ID NO:93, SEQ ID NO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, and the second nucleotide sequence encodes a phosphate acetyltransferase protein that retains the activity of a protein encoded by SEQ IDNO:l, SEQIDNO:3, SEQIDNO:5, SEQIDNO:33, SEQIDNO:35, SEQIDNO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQIDNO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, yet the second nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ IDNO:l, SEQIDNO:3, SEQIDNO:5, SEQIDNO:33, SEQIDNO:35, SEQIDNO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQIDNO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the transformed cell does not comprise a deletion, mutation, or substitution in a native pyruvate decarboxylase gene. In some embodiments, the transformed cell does not comprise a deletion, mutation, or substitution in a native gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate, or acetyl- CoA. In some embodiments, the transformed cell comprises a pyruvate decarboxylase protein. 1. Decreasing the activity of a phosphofructokinase protein, fructose- bisphosphate aldolase protein, and/or triose phosphate isomerase protein

Decreasing the activity of a native phosphofructokinase protein, a native fructose- bisphosphate aldolase protein, or a native triose phosphate isomerase protein obstructs a cellular pathway that competes with the phosphoketolase pathway, thereby increasing the utilization of the phosphoketolase pathway (Figure 2).

a. Decreasing the activity of a phosphofructokinase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native phosphofructokinase protein in the cell, e.g., the cell may comprise a knockout mutation in a native phosphofructokinase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native phosphofructokinase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native phosphofructokinase gene and/or a nucleotide sequence in the regulatory region of a native phosphofructokinase gene.

The phosphofructokinase protein may be classified by Enzyme Commission number EC 2.7.1.11.

b. Decreasing the activity of a fructose-bisphosphate aldolase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native fructose-bisphosphate aldolase protein in the cell, e.g., the cell may comprise a knockout mutation in a native fructose-bisphosphate aldolase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native fructose-bisphosphate aldolase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native fructose-bisphosphate aldolase gene and/or a nucleotide sequence in the regulatory region of a native fructose-bisphosphate aldolase gene.

The fructose-bisphosphate aldolase protein may be classified by Enzyme

Commission number EC 4.1.2.13.

c. Decreasing the activity of a triose phosphate isomerase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native triose phosphate isomerase protein in the cell, e.g., the cell may comprise a knockout mutation in a native triose phosphate isomerase gene. In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native triose phosphate isomerase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native triose phosphate isomerase gene and/or a nucleotide sequence in the regulatory region of a native triose phosphate isomerase gene.

The triose phosphate isomerase protein may be classified by Enzyme Commission number EC 5.3.1.1.

2. Increasing the activity of a fructose- 1, 6-bisphosphatase protein and decreasing the activity of a phosphofructokinase protein

Increasing the activity of a fructose- 1, 6-bisphosphatase protein in a cell increases the conversion of glyceraldehyde-3 -phosphate to glucose-6-phosphate, which provides a sink for the glyceraldehyde-3 -phosphate product of the phosphoketolase reaction and increases the concentration of the glucose-6-phosphate precursor, thereby increasing the utilization of the phosphoketolase pathway (Figure 3). Decreasing the activity of a native phosphofructokinase protein obstructs a cellular pathway that competes with the fructose- 1, 6-bisphosphatase pathway, thereby increasing the utilization of the fructose- 1,6- bisphosphatase pathway.

a. Increasing the activity of a fructose-1, 6-bisphosphatase protein

In some embodiments, the transformed cell comprises a third genetic modification, wherein said third genetic modification increases the activity of a fructose- 1,6- bisphosphatase protein in the cell. The third genetic modification may be transformation with a third nucleic acid, and the third nucleic acid may encode a fructose-1, 6- bisphosphatase protein.

In some embodiments, the method comprises transforming the cell with a third nucleotide sequence, wherein said third nucleotide sequence increases the activity of a fructose- 1, 6-bisphosphatase protein in the cell. For example, the third nucleotide sequence may encode a fructose- 1, 6-bisphosphatase protein.

The fructose-1, 6-bisphosphatase protein may be classified by Enzyme Commission number EC 3.1.3.11.

b. Decreasing the activity of a phosphofructokinase protein

In some embodiments, the transformed cell comprises a fourth genetic modification that decreases the activity of a native phosphofructokinase protein in the cell, e.g., the cell may comprise a knockout mutation in a native phosphofructokinase gene. In some embodiments, the method further comprises transforming the cell with a fourth nucleotide sequence, wherein said fourth nucleotide sequence decreases the activity of a native phosphofructokinase protein in the cell. For example, the fourth nucleotide sequence may be capable of recombining with a nucleotide sequence in a native

phosphofructokinase gene and/or a nucleotide sequence in the regulatory region of a native phosphofructokinase gene.

The phosphofructokinase protein may be classified by Enzyme Commission number EC 2.7.1.11.

c. Decreasing the activity of a transaldolase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native transaldolase protein in the cell, e.g., the cell may comprise a knockout mutation in a native transaldolase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native transaldolase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native transaldolase gene and/or a nucleotide sequence in the regulatory region of a native transaldolase gene.

The transaldolase protein may be classified by Enzyme Commission number EC

2.2.1.2.

d. Decreasing the activity of a glyceraldehyde 3-phosphate dehydrogenase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native glyceraldehyde 3-phosphate dehydrogenase protein in the cell, e.g., the cell may comprise a knockout mutation in a native glyceraldehyde 3- phosphate dehydrogenase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native glyceraldehyde 3-phosphate dehydrogenase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native glyceraldehyde 3-phosphate

dehydrogenase gene and/or a nucleotide sequence in the regulatory region of a native glyceraldehyde 3-phosphate dehydrogenase gene.

The glyceraldehyde 3-phosphate dehydrogenase protein may be classified by Enzyme Commission number EC 1.2.1.12. e. Decreasing the activity of a phosphoglycerate kinase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native phosphoglycerate kinase protein in the cell, e.g., the cell may comprise a knockout mutation in a native phosphoglycerate kinase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native phosphoglycerate kinase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native phosphoglycerate kinase gene and/or a nucleotide sequence in the regulatory region of a native phosphoglycerate kinase gene.

The phosphoglycerate kinase protein may be classified by Enzyme Commission number EC 2.7.2.3.

£ Decreasing the activity of a phosphoglycerate mutase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native phosphoglycerate mutase protein in the cell, e.g., the cell may comprise a knockout mutation in a native phosphoglycerate mutase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native phosphoglycerate mutase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native phosphoglycerate mutase gene and/or a nucleotide sequence in the regulatory region of a native phosphoglycerate mutase gene.

The phosphoglycerate mutase protein may be classified by Enzyme Commission number EC 5.4.2.11.

g. Decreasing the activity of an enolase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native enolase protein in the cell, e.g., the cell may comprise a knockout mutation in a native enolase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native enolase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native enolase gene and/or a nucleotide sequence in the regulatory region of a native enolase gene.

The enolase protein may be classified by Enzyme Commission number EC 4.2.1.11. h. Decreasing the activity of a pyruvate kinase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native pyruvate kinase protein in the cell, e.g., the cell may comprise a knockout mutation in a native pyruvate kinase gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native pyruvate kinase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native pyruvate kinase gene and/or a nucleotide sequence in the regulatory region of a native pyruvate kinase gene.

The pyruvate kinase protein may be classified by Enzyme Commission number EC

2.7.1.40.

L Increasing the activity of an oxidoreductase protein

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a oxidoreductase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a oxidoreductase protein.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a oxidoreductase protein in the cell. For example, the nucleotide sequence may encode a oxidoreductase protein.

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a NADPH external oxidoreductase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a NADPH external oxidoreductase protein.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a NADPH external oxidoreductase protein in the cell. For example, the nucleotide sequence may encode a NADPH external oxidoreductase protein.

j. Increasing the activity of a soluble transhydrogenase protein

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a transhydrogenase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a

transhydrogenase protein. In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a transhydrogenase protein in the cell. For example, the nucleotide sequence may encode a transhydrogenase protein.

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a soluble NADPH:NADH transhydrogenase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a soluble NADPFFNADH transhydrogenase protein.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a soluble NADPFFNADH

transhydrogenase protein in the cell. For example, the nucleotide sequence may encode a soluble NADPFFNADH transhydrogenase protein.

C. Cells comprising pyruvate decarboxylase activity, phosphate acetyltransferase activity, and acetate kinase activity

Increasing the activity of a pyruvate decarboxylase, phosphate acetyltransferase and acetate kinase in a cell allows the cell to produce acetyl-CoA from pyruvate in the cytosol (Figure 4).

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, a second genetic modification, and a third genetic modification, wherein said first genetic modification increases the activity of a pyruvate decarboxylase protein in the cell, said second genetic modification increases the activity of a phosphate acetyltransferase protein in the cell, and said third genetic modification increases the activity of an acetate kinase in the cell. In some embodiments, the transformed cell produces acetyl-CoA from pyruvate in the cytosol. In some embodiments, the transformed cell does not produce acetyl-CoA from pyruvate in the cytosol, e.g., the cell may convert pyruvate or a different substrate into acetyl-CoA or a different product; or, e.g., the cell may serve as a host cell for molecular cloning.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a pyruvate decarboxylase protein, transforming said cell with a second nucleotide sequence that encodes a phosphate acetyltransferase protein, and transforming said cell with a third nucleotide sequence that encodes an acetate kinase protein. In some embodiments, the method increases the lipid content of a cell by the cytosolic production of acetyl-CoA from pyruvate. In some embodiments, the method increases the lipid content of a cell through a molecular pathway other than by the cytosolic production of acetyl-CoA from pyruvate, e.g., the transformed cell may utilize the pyruvate decarboxylase, phosphate acetyltransferase, and/or acetate kinase proteins to convert pyruvate or a different substrate into acetyl-CoA or a different product. For example, the pyruvate decarboxylase, phosphate acetyltransferase, and/or acetate kinase may catalyze steps in a different metabolic pathway that either increases lipid biosynthesis or decreases lipid degradation.

a. Increasing the activity of a pyruvate decarboxylase protein

In some embodiments, the pyruvate decarboxylase protein is classified by Enzyme Commission number EC 4.1.1.1.

The pyruvate decarboxylase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11, or a biologically active portion of any one of them. For example, the pyruvate decarboxylase protein may be substantially identical to SEQ ID

NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11, and retain the functional activity of the protein of SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the pyruvate decarboxylase protein comprises the amino acid sequence set forth in SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11.

The first genetic modification may be transformation with a first nucleic acid, and the first nucleic acid may encode a pyruvate decarboxylase protein, i.e., the first nucleic acid may comprise a first nucleotide sequence that encodes a pyruvate decarboxylase protein.

In some embodiments, the first nucleotide sequence has at least 70%, 71%, 72%,

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:8, SEQ ID NO: 10, or SEQ ID NO: 12. For example, the first nucleotide sequence may have the sequence set forth in SEQ ID NO:8, SEQ ID NO: 10, or SEQ ID NO: 12. In some embodiments, the first nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, and the first nucleotide sequence encodes a pyruvate decarboxylase protein that retains the activity of a protein encoded by SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11, yet the first nucleotide sequence differs from the sequence set forth in SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the first nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%), 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11, or a biologically active portion of any one of them. For example, the first nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11. In some embodiments, the first nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11, and the first nucleotide sequence encodes a pyruvate decarboxylase protein that retains the activity of a protein encoded by SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11, yet the first nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO: 11, e.g., due to either natural allelic variation or mutagenesis.

b. Increasing the activity of a phosphate acetyltransferase protein

In some embodiments, the phosphate acetyltransferase protein is classified by Enzyme Commission number EC 2.2.1.8.

The phosphate acetyltransferase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%), 99.8%), 99.9%) or more sequence homology with the sequence set forth in SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, or a biologically active portion of any one of them. For example, the phosphate acetyltransferase protein may be substantially identical to SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, and retain the functional activity of the protein of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO:5, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the phosphate acetyltransferase protein comprises the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: l l l, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119.

The second genetic modification may be transformation with a second nucleic acid, and the second nucleic acid may encode a phosphate acetyltransferase protein, i.e., the second nucleic acid may comprise a second nucleotide sequence that encodes a phosphate acetyltransferase protein.

In some embodiments, the second nucleotide sequence has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%,

99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120. For example, the second nucleotide sequence may have the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120. In some embodiments, the second nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO:74, SEQ ID NO:76, SEQ ID NO:78, SEQ ID NO:80, SEQ ID NO:82, SEQ ID NO:84, SEQ ID NO:86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120, and the second nucleotide sequence encodes a phosphate acetyltransferase protein that retains the activity of a protein encoded by SEQ ID NO: l, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID N0:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, yet the second nucleotide sequence differs from the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54, SEQ ID NO:56, SEQ ID NO:58, SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, SEQ ID NO:68, SEQ ID NO:70, SEQ ID NO:72, SEQ ID NO:74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO:88, SEQ ID NO:90, SEQ ID NO:92, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO: 98, SEQ ID NO: 100, SEQ ID NO: 102, SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO: 108, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, or SEQ ID NO: 120, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the second nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%), 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, or a biologically active portion of any one of them. For example, the second nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID N0:91, SEQ ID NO:93, SEQ ID NO:95, SEQ ID NO:97, SEQ ID NO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO:109, SEQIDNO:lll, SEQIDNO:113, SEQIDNO:115, SEQIDNO:117, or SEQ ID NO: 119. In some embodiments, the second nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQIDNO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, and the second nucleotide sequence encodes a phosphate acetyltransferase protein that retains the activity of a protein encoded by SEQ IDNO:l, SEQIDNO:3, SEQIDNO:5, SEQIDNO:33, SEQIDNO:35, SEQIDNO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQIDNO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID

NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, yet the second nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ IDNO:l, SEQIDNO:3, SEQIDNO:5, SEQIDNO:33, SEQIDNO:35, SEQIDNO:37 SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQIDNO:51, SEQIDNO:53, SEQIDNO:55, SEQIDNO:57, SEQIDNO:59, SEQ ID NO:61, SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:71, SEQ ID NO:73, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:81, SEQ ID NO:83, SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:89, SEQ ID NO:91, SEQ ID NO:93, SEQIDNO:95, SEQIDNO:97, SEQIDNO:99, SEQ ID NO: 101, SEQ ID NO: 103, SEQ ID NO: 105, SEQ ID NO: 107, SEQ ID NO: 109, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, or SEQ ID NO: 119, e.g., due to either natural allelic variation or mutagenesis.

c. Increasing the activity of an acetate kinase protein

In some embodiments, the acetate kinase protein is classified by Enzyme

Commission number EC 2.7.2.1.

The acetate kinase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%) or more sequence homology with the sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, or a biologically active portion of any one of them. For example, the acetate kinase protein may be substantially identical to SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, and retain the functional activity of the protein of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the acetate kinase protein comprises the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139.

The third genetic modification may be transformation with a third nucleic acid, and the third nucleic acid may encode an acetate kinase protein, i.e., the third nucleic acid may comprise a third nucleotide sequence that encodes an acetate kinase protein.

In some embodiments, the third nucleotide sequence has at least 70%, 71%, 72%,

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, or SEQ ID NO: 140. For example, the third nucleotide sequence may have the sequence set forth in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, or SEQ ID NO: 140. In some embodiments, the third nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, or SEQ ID NO: 140 and the third nucleotide sequence encodes an acetate kinase protein that retains the activity of a protein encoded by SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, yet the third nucleotide sequence differs from the sequence set forth in SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 134, SEQ ID NO: 136, SEQ ID NO: 138, or SEQ ID NO: 140, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the third nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%), 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, or a biologically active portion of any one of them. For example, the third nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139. In some embodiments, the third nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, and the third nucleotide sequence encodes an acetate kinase protein that retains the activity of a protein encoded by SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, yet the third nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 127, SEQ ID NO: 129, SEQ ID NO: 131, SEQ ID NO: 133, SEQ ID NO: 135, SEQ ID NO: 137, or SEQ ID NO: 139, e.g., due to either natural allelic variation or mutagenesis.

d. Increasing the activity of a acetaldehyde dehydrogenase protein

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a acetaldehyde dehydrogenase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a acetaldehyde dehydrogenase protein.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a acetaldehyde dehydrogenase protein in the cell. For example, the nucleotide sequence may encode a acetaldehyde dehydrogenase protein.

In some embodiments, the transformed cell further comprises a genetic modification that increases the activity of a NADP-acetaldehyde dehydrogenase protein in the cell. For example, the genetic modification may be transformation with a nucleic acid that encodes a NADP-acetaldehyde dehydrogenase protein.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that increases the activity of a NADP-acetaldehyde dehydrogenase protein in the cell. For example, the nucleotide sequence may encode a NADP- acetaldehyde dehydrogenase protein.

In some embodiments, the acetaldehyde dehydrogenase protein is classified by Enzyme Commission number EC 1.2.1.4.

The acetaldehyde dehydrogenase protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 17, or a biologically active portion thereof. For example, the acetaldehyde

dehydrogenase protein may be substantially identical to SEQ ID NO: 17, and retain the functional activity of the protein of SEQ ID NO: 17, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the acetaldehyde dehydrogenase protein comprises the amino acid sequence set forth in SEQ ID NO: 17.

The genetic modification may be transformation with a nucleic acid that encodes a acetaldehyde dehydrogenase protein, i.e., the nucleic acid may comprise a nucleotide sequence that encodes a acetaldehyde dehydrogenase protein.

In some embodiments, the nucleotide sequence has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 18. For example, the nucleotide sequence may have the sequence set forth in SEQ ID NO: 18. In some embodiments, the nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO: 18, and the nucleotide sequence encodes a acetaldehyde dehydrogenase protein that retains the activity of a protein encoded by SEQ ID NO: 17, yet the nucleotide sequence differs from the sequence set forth in SEQ ID NO: 18, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%), 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 17, or a biologically active portion thereof. For example, the nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 17. In some embodiments, the nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 17, and the nucleotide sequence encodes a acetaldehyde dehydrogenase protein that retains the activity of a protein encoded by SEQ ID NO: 17, yet the nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 17, e.g., due to either natural allelic variation or mutagenesis.

e. Decreasing the activity of a pyruvate dehydrogenase complex protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native pyruvate dehydrogenase complex protein in the cell, e.g., the cell may comprise a knockout mutation in a native pyruvate dehydrogenase complex gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native pyruvate dehydrogenase complex protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native pyruvate dehydrogenase complex gene and/or a nucleotide sequence in the regulatory region of a native pyruvate dehydrogenase complex gene.

The pyruvate dehydrogenase complex protein may be classified by Enzyme Commission number EC 1.2.4.1, EC 2.3.1.12, or EC 1.8.1.4.

£_ Decreasing the activity of an ATP. -citrate lyase protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native ATPxitrate lyase protein in the cell, e.g., the cell may comprise a knockout mutation in a native ATPxitrate lyase kinase gene. In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native ATPxitrate lyase protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native ATPxitrate lyase gene and/or a nucleotide sequence in the regulatory region of a native ATPxitrate lyase gene.

The ATPxitrate lyase protein may be classified by Enzyme Commission number EC 2.3.3.8.

D. Cells comprising citrate/oxaloacetate mitochondrial transporter activity, cytosolic malic enzyme activity, and cytosolic pyruvate carboxylase activity

Increasing the activity of a citrate/oxaloacetate mitochondrial transporter, cytosolic malic enzyme, and cytosolic pyruvate carboxylase in a cell allows the cell to more efficiently synthesize fatty acids from cytosolic citrate (Figure 5).

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, a second genetic modification, and a third genetic modification, wherein said first genetic modification increases the activity of a citrate/oxaloacetate mitochondrial transporter protein in the cell, said second genetic modification increases the activity of a cytosolic malic enzyme protein in the cell, and said third genetic modification increases the activity of a cytosolic pyruvate carboxylase protein in the cell. In some embodiments, the transformed cell synthesizes fatty acids from cytosolic citrate. In some embodiments, the transformed cell does not synthesize fatty acids from cytosolic citrate, e.g., the cell may increase its production of fatty acids from other substrates; or, e.g., the cell may serve as a host cell for molecular cloning.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein, transforming said cell with a second nucleotide sequence that encodes a cytosolic malic enzyme protein, and transforming said cell with a third nucleotide sequence that encodes a cytosolic pyruvate carboxylase protein. In some embodiments, the method increases the lipid content of a cell by enabling the cell to more efficiently produce fatty acids from cytosolic citrate through production of cytosolic NADPH from cytosolic NADH generated during glycolysis. In the native pathway, glycolytic NADH is imported to the mitochondria during malate/citrate exchange across the mitochondrial membrane. In some embodiments, the method increases the lipid content of a cell through a molecular pathway other than the production of fatty acids from cytosolic citrate, e.g., increased cytosolic citrate may increase the production of lipids from a different substrate, or increased cytosolic citrate may decrease the degradation of lipids.

a. Increasing the activity of a citrate/oxaloacetate mitochondrial transporter protein

The citrate/oxaloacetate mitochondrial transporter protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 19, or a biologically active portion thereof. For example, the citrate/oxaloacetate mitochondrial transporter protein may be substantially identical to SEQ ID NO: 19, and retain the functional activity of the protein of SEQ ID NO: 19, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the citrate/oxaloacetate mitochondrial transporter protein comprises the amino acid sequence set forth in SEQ ID NO: 19.

The first genetic modification may be transformation with a first nucleic acid, and the first nucleic acid may encode a citrate/oxaloacetate mitochondrial transporter protein, i.e., the first nucleic acid may comprise a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein.

In some embodiments, the first nucleotide sequence has at least 70%, 71%, 72%,

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:20. For example, the first nucleotide sequence may have the sequence set forth in SEQ ID NO:20. In some embodiments, the first nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO:20, and the first nucleotide sequence encodes a citrate/oxaloacetate mitochondrial transporter protein that retains the activity of a protein encoded by SEQ ID NO: 19, yet the first nucleotide sequence differs from the sequence set forth in SEQ ID NO:20, e.g., due to either natural allelic vari ati on or mutagene si s .

In some embodiments, the first nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%), 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 19, or a biologically active portion thereof. For example, the first nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the first nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 19, and the first nucleotide sequence encodes a citrate/oxaloacetate mitochondrial transporter protein that retains the activity of a protein encoded by SEQ ID NO: 19, yet the first nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 19, e.g., due to either natural allelic variation or mutagenesis.

b. Increasing the activity of a cytosolic malic enzyme protein

In some embodiments, the cytosolic malic enzyme protein is classified by Enzyme Commission number EC 1.1.1.39 or 1.1.1.40.

The second genetic modification may be transformation with a second nucleic acid, and the second nucleic acid may encode a cytosolic malic enzyme protein, i.e., the second nucleic acid may comprise a second nucleotide sequence that encodes a cytosolic malic enzyme protein.

c. Increasing the activity of a cytosolic pyruvate carboxylase protein

The third genetic modification may be transformation with a third nucleic acid, and the third nucleic acid may encode a cytosolic pyruvate carboxylase protein, i.e., the third nucleic acid may comprise a third nucleotide sequence that encodes a cytosolic pyruvate carboxylase protein.

d. Decreasing the activity of a citrate/malate mitochondrial transporter protein In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native citrate/malate mitochondrial transporter protein in the cell, e.g., the cell may comprise a knockout mutation in a native citrate/malate

mitochondrial transporter complex gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native citrate/malate mitochondrial transporter protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native citrate/malate mitochondrial transporter gene and/or a nucleotide sequence in the regulatory region of a native citrate/malate mitochondrial transporter gene. E. Cells comprising citrate/oxaloacetate mitochondrial transporter activity and enoyl acyl-carrier reductase activity

Increasing the activity of a citrate/oxaloacetate mitochondrial transporter and an enoyl acyl-carrier reductase in a cell allows the cell to more efficiently synthesize fatty acids from cytosolic citrate (Figure 6).

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, and a second genetic modification, wherein said first genetic modification increases the activity of a citrate/oxaloacetate mitochondrial transporter protein in the cell, and said second genetic modification increases the enoyl acyl-carrier reductase activity of the cell. In some embodiments, the transformed cell synthesizes fatty acids from cytosolic citrate. In some embodiments, the transformed cell does not synthesize fatty acids from cytosolic citrate, e.g., the cell may increase its production of fatty acids from other substrates; or, e.g., the cell may serve as a host cell for molecular cloning.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein, and transforming said cell with a second nucleotide sequence. The second nucleotide sequence may either encode a enoyl acyl-carrier reductase protein, or the second nucleotide sequence may be capable of recombining with a nucleotide sequence in a native type I fatty acid synthase enoyl reductase gene; and transformation of the cell with the second nucleotide sequence may increase the enoyl acyl-carrier reductase activity of the cell. In some embodiments, the method increases the lipid content of a cell by enabling the cell to produce fatty acids more efficiently from cytosolic citrate. In some embodiments, the method increases the lipid content of a cell through a molecular pathway other than the production of fatty acids from cytosolic citrate, e.g., increased cytosolic citrate may increase the production of lipids from a different substrate, or increased cytosolic citrate may decrease the degradation of lipids.

In some embodiments, the invention relates to a transformed cell, comprising a first genetic modification, and a second genetic modification, wherein said first genetic modification increases the activity of a citrate/oxaloacetate mitochondrial transporter protein in the cell, and said second genetic modification increases the NADH-specific enoyl acyl-carrier reductase activity of the cell. In some embodiments, the transformed cell synthesizes fatty acids from cytosolic citrate. In some embodiments, the transformed cell does not synthesize fatty acids from cytosolic citrate, e.g., the cell may increase its production of fatty acids from other substrates; or, e.g., the cell may serve as a host cell for molecular cloning.

In some embodiments, the invention relates to methods of increasing the lipid content of a cell, comprising transforming said cell with a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein, and transforming said cell with a second nucleotide sequence. The second nucleotide sequence may either encode a NADH specific enoyl acyl-carrier reductase protein, or the second nucleotide sequence may be capable of recombining with a nucleotide sequence in a native type I fatty acid synthase enoyl reductase gene; and transformation of the cell with the second nucleotide sequence may increase the NADH specific enoyl acyl-carrier reductase activity of the cell. In some embodiments, the method increases the lipid content of a cell by enabling the cell to produce fatty acids more efficiently from cytosolic citrate. In some embodiments, the method increases the lipid content of a cell through a molecular pathway other than the production of fatty acids from cytosolic citrate, e.g., increased cytosolic citrate may increase the production of lipids from a different substrate, or increased cytosolic citrate may decrease the degradation of lipids.

a. Increasing the activity of a citrate/oxaloacetate mitochondrial transporter protein

The citrate/oxaloacetate mitochondrial transporter protein may comprise an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 19, or a biologically active portion thereof. For example, the citrate/oxaloacetate mitochondrial transporter protein may be substantially identical to SEQ ID NO: 19, and retain the functional activity of the protein of SEQ ID NO: 19, yet differ in amino acid sequence, e.g., due to either natural allelic variation or mutagenesis. In some embodiments, the citrate/oxaloacetate mitochondrial transporter protein comprises the amino acid sequence set forth in SEQ ID NO: 19.

The first genetic modification may be transformation with a first nucleic acid, and the first nucleic acid may encode a citrate/oxaloacetate mitochondrial transporter protein, i.e., the first nucleic acid may comprise a first nucleotide sequence that encodes a citrate/oxaloacetate mitochondrial transporter protein. In some embodiments, the first nucleotide sequence has at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO:20. For example, the first nucleotide sequence may have the sequence set forth in SEQ ID NO:20. In some embodiments, the first nucleotide sequence is substantially identical to the sequence set forth in SEQ ID NO:20, and the first nucleotide sequence encodes a citrate/oxaloacetate mitochondrial transporter protein that retains the activity of a protein encoded by SEQ ID NO: 19, yet the first nucleotide sequence differs from the sequence set forth in SEQ ID NO:20, e.g., due to either natural allelic variation or mutagenesis.

In some embodiments, the first nucleotide sequence encodes an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more sequence homology with the sequence set forth in SEQ ID NO: 19, or a biologically active portion thereof. For example, the first nucleotide sequence may encode the amino acid sequence set forth in SEQ ID NO: 19. In some embodiments, the first nucleotide sequence encodes an amino acid sequence that is substantially identical to the sequence set forth in SEQ ID NO: 19, and the first nucleotide sequence encodes a citrate/oxaloacetate mitochondrial transporter protein that retains the activity of a protein encoded by SEQ ID NO: 19, yet the first nucleotide sequence encodes an amino acid sequence that differs from the sequence set forth in SEQ ID NO: 19, e.g., due to either natural allelic variation or mutagenesis.

b. Increasing enoyl acyl-carrier reductase activity

In some embodiments, the second genetic modification may be transformation with a second nucleic acid, and the second nucleic acid may encode an enoyl acyl-carrier reductase protein, i.e., the second nucleic acid may comprise a second nucleotide sequence that encodes an enoyl acyl-carrier reductase protein.

In some embodiments, the second genetic modification may be transformation with a second nucleic acid, and the second nucleic acid may encode a NADH-specific enoyl acyl-carrier reductase protein, i.e., the second nucleic acid may comprise a second nucleotide sequence that encodes a NADH-specific enoyl acyl-carrier reductase protein. The NADH specific enoyl acyl-carrier reductase protein may be classified by Enzyme Commission number EC 1.3.1.9.

In some embodiments, the second genetic modification is a mutation to a native type I fatty acid synthase enoyl reductase protein, wherein the mutation increases the ability of the native type I fatty acid synthase enoyl reductase protein to accept NADH as an electron donor.

In some embodiments, the method comprises transforming the cell with a second nucleotide sequence that is capable of recombining with a nucleotide sequence in a native type I fatty acid synthase enoyl reductase gene to generate a mutation that increases the ability of the native type I fatty acid synthase enoyl reductase protein gene product to accept NADH as an electron donor.

c. Decreasing the activity of a citrate/malate mitochondrial transporter protein

In some embodiments, the transformed cell further comprises a genetic modification that decreases the activity of a native citrate/malate mitochondrial transporter protein in the cell, e.g., the cell may comprise a knockout mutation in a native citrate/malate

mitochondrial transporter complex gene.

In some embodiments, the method further comprises transforming the cell with a nucleotide sequence that decreases the activity of a native citrate/malate mitochondrial transporter protein in the cell. For example, the nucleotide sequence may be capable of recombining with a nucleotide sequence in a native citrate/malate mitochondrial transporter gene and/or a nucleotide sequence in the regulatory region of a native citrate/malate mitochondrial transporter gene.

F. Products

In some aspects, the invention relates to a method of producing a product, comprising providing a transformed cell, and culturing the cell for a period of time on a substrate, thereby producing the product.

The substrate may comprise depolymerized sugar beet pulp, glycerin, black liquor, corn, corn starch, corn dextrins, depolymerized cellulosic material, corn stover, sugar beet pulp, switchgrass, milk whey, molasses, potato, rice, sorghum, sugar cane, thick cane juice, sugar beet juice, and/or wheat. In certain embodiments, the transformed cells are grown in the presence of exogenous fatty acids, glucose, ethanol, xylose, sucrose, starch, starch dextrin, glycerol, cellulose, and/or acetic acid. These compounds may be added to the substrate during cultivation to increase lipid production. The exogenous fatty acids may include stearate, oleic acid, linoleic acid, γ-linolenic acid, dihomo-y-linolenic acid, arachidonic acid, a-linolenic acid, stearidonic acid, eicosatetraenoic acid, eicosapenteaenoic acid, docosapentaenoic acid, eicosadienoic acid, and/or eicosatrienoic acid.

In certain embodiments, the present invention relates to a product produced by a modified host cell described herein. In certain embodiments, the product is an oil, lipid, fatty acid, fatty alcohol, triacylglyceride, isoprenoid, or farnesene. In some embodiments, the product is stearic acid, oleic acid, linoleic acid, capric acid, caprylic acid, caproic acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, or squalene. In certain

embodiments, the product is a saturated fatty acid. Thus, the product may be caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, lignoceric acid, or cerotic acid. In some embodiments, the product is an unsaturated fatty acid. Thus, the product may be myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, vaccenic acid, linoleic acid, linoelaidic acid, α-linolenic acid, arachidonic acid, eicosapenteaenoic acid, erucic acid, or docosahexaenoic acid.

In some embodiments, the product comprises an 18-carbon fatty acid. In some embodiments, the product comprises oleic acid, stearic acid, or linoleic acid. For example, the product may be oleic acid.

In some embodiments, the method comprises collecting the product. The method may comprise purifying the product, e.g., separating one or more lipid fractions from a culture of transformed cells from one or more aqueous fractions of the culture.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The embodiments described herein are not intended as limitations on the scope of the invention.

EXEMPLIFICATION

Example 1 - Expression of phosphoketolase in yeast

The phosphoketolase gene from Trichoderma reesei (NG306; SEQ ID NO:28) was cloned into Saccharomyces cerevisiae strain NS20. The phosphoketolase genes from Trichoderma reesei (NG306; SEQ ID NO:28) and Aspergillus niger (NG304; SEQ ID NO:24) were cloned, separately, into Arxula adeninivorans strain NS252.

Example 2 - Expression of phosphate acetyltransferase in yeast

A construct was engineered to overexpress the phosphate acetyltransferase gene from Bacillus subtilis (NG321; SEQ ID NO: 116) in yeast (Figure 7). Similar constructs were used to overexpress phosphate acetyltransferase genes from Clostridium

acetobutylicum strain ATCC 824 (NG322; SEQ ID NO: 118), Thermoanaerobacterium saccharolyticum (NG324; SEQ ID NO: 120), Methanosarcina thermophila (NG309; SEQ ID NO:2), Methanosarcina barkeri strain Fusaro (NG310; SEQ ID NO:4), Methanosarcina acetivorans (NG311; SEQ ID NO:6), Aphanomyces astaci (NG350; SEQ ID NO:34), Aphanomyces invadans (NG351; SEQ ID NO: 36), Auxenochlorella protothecoides

(NG352; SEQ ID NO:38), Beauveria bassiana (NG353; SEQ ID NO:40), Chlamydomonas reinhardtii (NG354; SEQ ID NO:42), Guillardia theta (NG356; SEQ ID NO:46),

Helicosporidium (NG357; SEQ ID NO:48), Perkinsus marinus (NG358; SEQ ID NO:50), Phytophthora parasitica (NG361; SEQ ID NO:56), Phytophthora ramorum (NG362; SEQ ID NO: 58), Phytophthora sojae (NG363; SEQ ID NO: 60), Pythium ultimum (NG364; SEQ ID NO: 62), Saprolegnia diclina (NG365; SEQ ID NO: 64), Selaginella moellendorffii (NG367; SEQ ID NO:68), Volvox carteri (NG369; SEQ ID NO:72), Bacillus subtilis subsp. subtilis strain 168 (NG370; SEQ ID NO:74), and Thermoanaerobacterium saccharolyticum (NG371 ; SEQ ID NO : 76) in yeast.

The constructs were used to transform Saccharomyces cerevisiae strain NS20, Yarrowia lipolytica strain NS18, and Arxula adeninivorans strain NS252. Transformants were screened for phosphate acetyltransferase activity using an assay described by Bock et al. (J. Bacteriology 181(6): 1861-67 (1999)). Briefly, cell-free extracts were prepared from 5ml overnight YPD cultures using the Y-PER® Plus, Dialyzable Yeast Protein Extraction Reagent (Pierce Biotechnologies, catalog #78999). Cells were pelleted by centrifugation at 3000 rpm for 3 minutes and resuspended in 125-250 μΐ Y-PER Reagent per 50 mg cells by vortexing. 5μ1 Thermo Scientific™ Pierce™ Protease Inhibitors (catalog # PI-36978) were added per 1 mL of the Y-PER Plus/cell mixture. The mixture was agitated and allowed to sit at room temperature for 20 minutes. Cell debris was pelleted by centrifugation at 14,000 x g for 10 minutes, and the supernatant was stored at -80°C until use.

10-80 μΐ of the cell-free extracts were added to acetyl-CoA reaction mixtures comprising a final concentration of 100 mM Tris-HCL (pH 7.2), 5 mM MgCl ₂ , 5 mM KH ₂ P0 ₄ , and 0.1 mM DTNB in 1 mL water. An acetyl-CoA substrate was added to a final concentration of 0.1 mM, and absorbance was monitored at 412 nm for 5-thio-2- nitrobenzoic acid (ε = 14.5 mM ^_1 cm ^_1 ).

Each S. cerevisiae cell transformed with a phosphate acetyltransferase gene produced more 5-thio-2-nitrobenzoic acid than a control S. cerevisiae cell transformed with a phosphoketolase gene from Trichoderma reesei (Figure 8). S. cerevisiae transformed with a phosphate acetyltransferase gene from either Bacillus subtilis (NG321; SEQ ID NO: 116) or Thermoanaerobacterium saccharolyticum (NG324; SEQ ID NO: 120) displayed superior performance in the phosphate acetyltransferase assay. The results were normalized by calculating specific activity, i.e., by dividing the rate of 5-thio-2-nitrobenzoic acid production by the amount of protein in each cell-free extract. Protein concentrations were measured using the Pierce™ Coomassie (Bradford) Protein Assay Kit. S. cerevisiae transformed with a phosphate acetyltransferase gene from either Bacillus subtilis (NG321; SEQ ID NO: 116) or Thermoanaerobacterium saccharolyticum (NG324; SEQ ID NO: 120) displayed more specific activity than a negative control (Figure 9).

The phosphate acetyltransferase gene from Bacillus subtilis (NG321; SEQ ID NO: 116) was codon optimized for yeast, resulting in SEQ ID NO: 74 (NG370). The phosphate acetyltransferase gene from Thermoanaerobacterium saccharolyticum (NG324; SEQ ID NO: 120) was codon optimized for yeast, resulting in SEQ ID NO:76 (NG371).

The specific activity for S. cerevisiae cell-extracts from cells transformed with phosphate acetyltransferase genes from either Aphanomyces astaci (NG350; SEQ ID NO:34), Aphanomyces invadans (NG351; SEQ ID NO:36), Auxenochlorella protothecoides (NG352; SEQ ID NO:38), Beauveria bassiana (NG353; SEQ ID NO:40), Chlamydomonas reinhardtii (NG354; SEQ ID NO:42), Guillardia theta (NG356; SEQ ID NO:46),

Helicosporidium (NG357; SEQ ID NO:48), Perkinsus marinus (NG358; SEQ ID NO:50), Phytophthora parasitica (NG361; SEQ ID NO:56), Phytophthora ramorum (NG362; SEQ ID NO: 58), Phytophthora sojae (NG363; SEQ ID NO: 60), Pythium ultimum (NG364; SEQ ID NO: 62), Saprolegnia diclina (NG365; SEQ ID NO: 64), Selaginella moellendorffii (NG367; SEQ ID NO: 68), or Volvox carteri (NG369; SEQ ID NO: 72) are shown in Figure 10.

Arxula adeninivorans strain NS252 was transformed with a phosphate

acetyltransferase gene from either Bacillus subtilis (NG321; SEQ ID NO: 116), Clostridium acetobutylicum strain ATCC 824 (NG322; SEQ ID NO: 118), Thermoanaerobacterium saccharolyticum (NG324; SEQ ID NO: 120), or Methanosarcina barkeri strain Fusaro (NG310; SEQ ID NO:4), and specific phosphate acetyltransferase activity was monitored (Figure 11) as described above. Strain NS252, transformed with phosphoketolase genes from either Trichoderma reesei (NG306; SEQ ID NO:28) or Aspergillus niger (NG304; SEQ ID NO:24), was assayed as negative controls. The phosphate acetyltransferase from Bacillus subtilis (NG321; SEQ ID NO: 116) displayed the highest activity.

Arxula adeninivorans strain NS252 was transformed with a phosphate

acetyltransferase gene from either Aphanomyces astaci (NG350; SEQ ID NO:34),

Aphanomyces invadans (NG351; SEQ ID NO: 36), Auxenochlorella protothecoides

(NG352; SEQ ID NO:38), Beauveria bassiana (NG353; SEQ ID NO:40), Chlamydomonas reinhardtii (NG354; SEQ ID NO:42), Guillardia theta (NG356; SEQ ID NO:46),

Helicosporidium (NG357; SEQ ID NO:48), Perkinsus marinus (NG358; SEQ ID NO:50), Phytophthora parasitica (NG361; SEQ ID NO:56), Phytophthora ramorum (NG362; SEQ ID NO : 58), Phytophthora sojae (NG363 ; SEQ ID NO : 60), Pythium ultimum (NG364; SEQ ID NO: 62), Saprolegnia diclina (NG365; SEQ ID NO: 64), Selaginella moellendorffii (NG367; SEQ ID NO: 68), or Volvox carteri (NG369; SEQ ID NO: 72), Bacillus subtilis subsp. subtilis strain 168 (NG370; SEQ ID NO:74), or Thermoanaerobacterium

saccharolyticum (NG371; SEQ ID NO: 76), and specific phosphate acetyltransferase activity was monitored (Figure 12) as described above. Each gene was transformed into A. adeninivorans using a construct similar to pNC582 (Figure 7) in which the NG321 gene is replaced with the phosphate acetyltransferase gene, under the control of the PR4 promoter from Y. lipolytica. Four transformants were analyzed for each construct. The phosphate acetyltransferase from Bacillus subtilis subsp. subtilis strain 168 (NG370; SEQ ID NO:74) displayed the highest activity.

Yarrowia lipolytica strain NS18 was transformed with a phosphate acetyltransferase gene from either Aphanomyces astaci (NG350; SEQ ID NO:34), Aphanomyces invadans (NG351; SEQ ID NO:36), Auxenochlorella protothecoides (NG352; SEQ ID NO:38), Beauveria bassiana (NG353; SEQ ID NO:40), Chlamydomonas reinhardtii (NG354; SEQ ID NO:42), Bacillus subtilis subsp. subtilis strain 168 (NG370; SEQ ID NO:74), or Thermoanaerobacterium saccharolyticum (NG371; SEQ ID NO: 76), and specific phosphate acetyltransferase activity was monitored (Figure 13) as described above. The phosphate acetyltransferases from Bacillus subtilis subsp. subtilis strain 168 (NG370; SEQ ID NO: 74) and Thermoanaerobacterium saccharolyticum (NG371; SEQ ID NO: 76) displayed the highest activity.

Yarrowia lipolytica strain NS18 was transformed with a phosphate acetyltransferase gene from either Per kinsus marinus (NG358; SEQ ID NO: 50), Phytophthora parasitica (NG361; SEQ ID NO:56), Phytophthora ramorum (NG362; SEQ ID NO:58), Phytophthora sojae (NG363; SEQ ID NO: 60), Pythium ultimum (NG364; SEQ ID NO: 62), Saprolegnia diclina (NG365; SEQ ID NO: 64), Selaginella moellendorffii (NG367; SEQ ID NO: 68), or Volvox carteri (NG369; SEQ ID NO: 72), and specific phosphate acetyltransferase activity was monitored (Figure 14) as described above.

Example 3 - Deletion of the 6-phosphofructokinase gene in yeast

The PFKl gene in Y. lipolytica encodes the 6-phosphofructokinase 1 protein PFKl (SEQ ID NO: 141). SEQ ID NO: 142 contains the PFKl nucleotide sequence, 100 upstream nucleotides, and 100 downstream nucleotides, and this sequence was used to design nucleic acids capable of recombining with the native Y. lipolytica 6-phosphofructokinase 1 gene to generate a PFKl knockout.

Knockout cassettes comprising the nucleotide sequences set forth in SEQ ID

NO: 143 and SEQ ID NO: 144 each comprise a portion of the nourseothricin resistance gene Nat as a marker. SEQ ID NO: 144 also comprises a negative selection marker gene thymidine kinase (TDK), which confers sensitivity to 5-fluoro-2'-deoxyuridine (FUdR). Neither SEQ ID NO: 143 nor SEQ ID NO: 144 encodes a functional protein, but the two sequences are capable of encoding a functional protein that confers nourseothricin resistance upon successful recombination. Further, SEQ ID NO: 143 does not contain a promoter and SEQ ID NO: 144 does not contain a terminator, and thus, they rely on homologous recombination with the Y. lipolytica PFKl gene in order for the Nat gene and the TDK gene to be transcribed and translated. In this way, successfully transformed cells may be selected by growing the cells on a medium containing nourseothricin. Additionally, transformed cells are unable to grow in FUdR-containing media due to the functional TDK gene. The TDK gene as a negative selection marker is added in order to facilitate the removal of the knockout cassette during a subsequent transformation, i.e., successful removal of the knockout cassette would mean the newly transformed cells would be able to grow on medium containing 5-fluoro-2'-deoxyuridine.

A knockout cassette for SEQ ID NO: 143 was prepared by amplifying a

nourseothricin resistance gene Nat (SEQ ID NO: 146) with primer NP2782 (SEQ ID

NO: 149) and primer NP356 (SEQ ID NO: 152). A knockout cassette for SEQ ID NO: 144 was prepared by amplifying the nourseothricin resistance gene Nat (SEQ ID NO: 146) and FUdR sensitive gene TDK (SEQ ID NO: 148) with primer NP355 (SEQ ID NO: 151) and primer NP2783 (SEQ ID NO: 150). The template vector used for these PCR reactions is the vector pNC468 (Figure 15). Similar knockout cassettes may be designed to reduce the activity of the PFKl gene of Arxula adeninivorans (SEQ ID NO: 154), the PFK2 gene of Arxula adeninivorans (SEQ ID NO: 156), or another known gene of Arxula or a different species.

Knockout cassettes for SEQ ID NO: 143 and SEQ ID NO: 144 were used to delete the PFKl gene from Yarrowia lipolytica strain NS18. PCR was used to check for the presence of an intact PFKl gene and to check for successful recombination of the SEQ ID NO: 143 and SEQ ID NO: 144 nucleotide sequences. Primer NP2784 (SEQ ID NO: 157) binds to a region upstream of the Y. lipolytica PFKl gene, primer NP2785 (SEQ ID

NO: 158) binds to an internal region of the PFKl gene, and the two primers were used to determine whether transformed cells comprised an intact PFKl gene. Figure 16 panel A shows that none of eight transformed colonies comprised an intact PFKl gene, whereas the untransformed negative control NG18 comprised an intact PFKl gene. Thus, the two knockout cassettes successfully deleted the PFKl gene in each transformant. Primer NP2784 (SEQ ID NO: 157) binds to a region upstream of the PFKl gene, primer NP356 (SEQ ID NO: 152) binds to the Nat gene, and the two primers were used to determine whether transformed cells comprised the knockout cassette. Figure 16 panel B shows that six of eight transformants contained a knockout cassette integrated into the PFKl gene locus. Colony 1, which comprises a PFKl deletion and integrated knockout cassette, was named strain NS807.

Wild type Yarrowia lipolytica strain NS18 and PFKl knockout strain NS807 were plated on minimal media containing glucose as the sole carbon source. Strain NS18 was able to grow on glucose whereas strain NS807 was not, thereby confirming the PFKl deletion in strain NS807 (Figure 17).

The phosphofructokinase activity of wild type Yarrowia lipolytica strain NS18 and PFKl knockout strain NS807 was assessed using a phosphofructokinase assay described by Flores et al. (Microbiology, 151 : 1465-74 (2005)). Protein was extracted from 2 L overnight cultures of each strain grown to an OD ₆ oo of 0.5-0.6. Cells were pelleted at 5000 rpm at 4°C and washed twice in 20 mM HEPES, pH 7.6, containing 1M sorbitol. Cell pellets were washed in lysis buffer containing 100 mM HEPES, pH 7.6, containing 0.8M sorbitol, 10 mM magnesium acetate, 2mM EDTA, and 300 mM potassium glutamate, and then suspended in a minimal volume of lysis buffer (approximately l/3rd of the pellet volume). The cells were frozen in liquid nitrogen and stored at -80°C. The cells were lysed in a coffee grinder with dry ice by grinding 15-20 times using 20-second pulses. The ground dry ice/cell mix was transferred into a centrifuge tube, and the dry ice was allowed to sublimate at room temperature. The cell debris was pelleted at 22,000 rpm for 30 minutes at 4°C, and the supernatant was stored at -80°C until use. The supernatant was used to assess phosphofructokinase activity as described by Flores et al. (Microbiology, 151 : 1465- 74 (2005)). Activity was normalized using total protein concentration, which was calculated using the Pierce™ Coomassie (Bradford) Protein Assay Kit. Deletion of the PFK1 gene from Y. lipolytica reduced PFK activity in strain NS807 relative to wild type strain NS 18 (Figure 18).

INCORPORATION BY REFERENCE

All of the patents, published patent applications, and non-patent literature cited herein are hereby incorporated by reference. EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.